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 First identified over a decade ago, Astrocyte Elevated Gene-1 (AEG-1) 
has been studied extensively due to early reports of its overexpression in various 
cancer cell lines. Research groups all over the globe including our own have 
since identified AEG-1 overexpression in cancers of diverse lineages including 
cancers of the liver, colon, skin, prostate, breast, lung, esophagus, neurons and 
neuronal glia as compared to matched normal tissue. A comprehensive and 
convincing body of data currently points to AEG-1 as an essential component, 
critical to the progression and perhaps onset of cancer. AEG-1 is a potent 
activator of multiple pro-tumorigenic signal transduction pathways such as 
mitogen-activated protein extracellular kinase (MEK)/ extracellular signal-
regulated kinase (ERK), phosphotidyl-inositol-3-kinase (PI3K)/Akt/mTOR, NF-κB 
and Wnt/β-catenin pathway. In addition, studies show that AEG-1 not only alters 
	  global gene and protein expression profiles, it also modulates fundamental 
intracellular processes, such as transcription, translation and RNA interference in 
cancer cells most likely by functioning as a scaffold protein.  
 The mechanisms by which AEG-1 is overexpressed in cancer have been 
studied extensively and it is clear that multiple layers of regulation including 
genomic amplification, transcriptional, posttranscriptional, and posttranslational 
controls are involved however; the mechanism by which AEG 1 itself induces its 
oncogenic effects is still poorly understood. Just as questions remain about the 
exact role of AEG-1 in carcinogenesis, very little is known about the role of AEG-
1 in regulating normal physiological functions in the liver. With the help of the 
Massey Cancer Center Transgenic/Knockout Mouse Core, our lab has 
successfully created a germline-AEG-1 knockout mouse (AEG-1-/-) as a model 
to interrogate AEG-1 function in vivo. Here I present the insights gained from 
efforts to analyze this novel AEG-1-/- mouse model. Aspects of the physiological 
functions of AEG-1 will be covered in chapter two wherein details of the 
characterization of the AEG-1-/- mouse are described including the role of AEG-1 
in lipid metabolism. Chapter three discusses novel discoveries about the specific 
role of AEG-1 in mediating hepatocarcinogenesis by modulating NF-κB, a critical 
inflammatory pathway.  
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Chapter One-Introduction 
 
 
I. Initial Identification and Cloning of Astrocyte Elevated Gene -1 
 
 In 2002, Su and colleagues set out to elucidate potential gene expression 
changes in HIV-1-infected astrocytes. Rapid subtraction hybridization (RaSH) 
was used as a method to identify differential expression between infected and 
non-infected primary human fetal astrocytes (PHFAs). Temporal cDNA libraries 
were prepared from double-stranded cDNAs, which were PCR amplified and 
then hybridized. Subtracting temporal cDNAs derived from uninfected astrocytes 
from temporal cDNAs made from HIV-1 infected astrocytes allowed for the 
identification of several human immunodeficiency virus (HIV)-1 and tumor 
necrosis factor (TNF)-α-inducible induced genes. These genes termed astrocyte 
elevated (AEGs) included both novel and previously characterized targets [1]. 
AEG-1 (also referred to as Metadherin, LYRIC, or 3D3/LYRIC in the literature) 
was among 15 of the novel genes identified.  AEG-1 was shown to be induced 
following exposure to HIV-1, its cell surface protein gp120, or upon exposure to 
the HIV-1-induced cytokine tumor necrosis factor-α (TNF-α). 
  The role of AEG-1 in HIV-1 was not pursued further however soon after 
the initial identification of AEG-1, another group cloned the murine ortholog of 
AEG-1 in a study aimed at identifying tumor cell surface molecules mediating 
metastasis of breast cancer cells using in vivo phage screening methods. In this 
	   	   2	  
	  
study a phage display library of breast carcinoma cDNAs enriched for secreted 
and transmembrane proteins from mouse 4T1 breast cancer cells was injected 
into mice intravenously. Phages that localized to the lungs were isolated and 
sequenced.  One of the clones identified in this study encoded amino acids 378-
440 of mouse AEG-1, and this particular extracellular protein domain was shown 
to specifically induce phage homing to the microvasculature of the lung. This was 
the first identification of the lung homing domain (LHD) in the protein they named 
metastasis adhesion protein-or metadherin [2].  Immunostaining revealed 
metadherin overexpression in breast cancer tissue and breast tumor xenografts 
as compared to normal breast tissue sections [2].  This study also showed that 
overexpressing metadherin in HEK293T cells enhanced lung localization of the 
cells while siRNA-mediated knockdown of metadherin inhibited the lung 
metastasis commonly seen in mouse 4T1 breast cancer cells. Additionally, the 
use of anti- metadherin antibodies reactive to the lung-homing domain of 
metadherin inhibited experimental breast cancer lung metastasis providing the 
first experimental evidence that this murine AEG-1 ortholog played an important 
role in cancer metastasis [2].  
 Also in 2004, gene-trapping techniques screening for proteins located at 
distinct sub-compartments of the nucleus led to the isolation of the mouse/rat 
AEG-1 by a separate group who assigned the name 3D3/lyric [3]. In this study F9 
embryonic carcinoma cells were transfected with a reporter gene possessing an 
upstream splice acceptor then allowed to fuse with trapped genes through 
splicing. Localization of the trapped genes was then determined by 
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immnostaining for the reporter gene. The N-terminal of 3D3/lyric was trapped 
using this method and found to localize at the nuclear membrane showing a 
unique, patchy distribution at the nuclear periphery [3]. Sub cellular fractionation 
and immunostaining showed that the 3D3/lyric protein was located primarily in 
the endoplasmic reticulum (ER), but staining was also observed in the nuclear 
envelope and the nucleolus making it a rare example of a protein that travels 
freely between the nuclear compartment and the ER. Concurrently another group 
reported cloning the rat AEG-1 homolog as a tight junction protein. This protein 
was found to have a strong interaction with carcinoembryonic antigen-related cell 
adhesion molecule 1 protein (CEACAM1), and was thus deemed LYsine-RIch 
CEACAM1 co-isolated (LYRIC) and the cDNA was cloned by expression library 
screening [4].   
 
II. Characterization of Astrocyte Elevated Gene-1 
 
BLAST comparison indicates that the AEG-1 gene is unique in that it has 
no structural similarity to any currently known genes [4].  AEG-1 homologues 
have been identified in a number of mammals with over 90% rate of identity 
however AEG-1 homologues have not been detected in invertebrates. Recently, 
Lee and Kang conducted a phylogenetic analysis probing DNA sequences for the 
AEG-1 gene in a wide range of vertebrates using computational phylogenetics 
methods. Bayesian inference using a GTR-Invariants-Gamma model with 1 
million generations was used to generate a phylogenetic tree (Fig 1.1). The data 
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that resulted illustrated the lines of evolutionary descent of the AEG-1 gene from 
a common ancestor and provided some new and interesting insights regarding 
the phylogenetic evolution of AEG-1. Extremely long branches or clades were 
observed in all mammalian species with the exception of primates and 
carnivores. The clade pattern with respect to the length is suggestive of a strong 
degree of purifying natural selection within the short-branched clades in the tree. 
Quantification of the lengths of the clades revealed a fourfold slower rate of 
change in the AEG-1 gene in primates and carnivores as compared to other 
mammals. This data indicates that AEG-1 arose in the common ancestor of all 
jawed vertebrates over 500 million years ago [5]. Taken together it may be 
presumed that not only is AEG-1 distinct to vertebrates, it may have been a part 
of the evolutionary process some 500 million years ago incorporated to perform 
specialized functions in higher vertebrates.  
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Figure	  1.1	  Bayesian	  phylogenetic	  tree.	  This	  tree	  depicts	  the	  relationship	  between	  
vertebrate	  AEG-­‐1/MTDH/LYRIC	  genes. 
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  The human AEG-1 gene has 12 exons and 11 introns and is located at 
chromosome 8q22-a region identified as a hotspot for recurrent amplification of 
several human cancer cells by cytogenetic analysis [6] [7] [8]. AEG-1 mRNA 
consists of 3611 nucleotides excluding the poly-A tail. The open reading frame 
(from nucleotide 220 to 1,968) of AEG-1 encodes a lysine-rich 64 kDa protein 
with an isoelectric point of 9.33 as determined by conceptual translational 
analysis using SMART and von Heijne's technique 9.33 [6].  
 AEG-1 is recognized as a single-pass transmembrane protein with 
putative transmembrane domain (TMD) spanning amino acid residues 51 to 72 
(Fig 1.2) as determined by analysis of its hydrophobic regions using PSORTII, 
InterProScan and Simple Modular Architecture Research Tool (SMART) [3]. A 
hidden Markov model used to predict protein membrane helices and protein 
topology predicted AEG-1 to be a protein with type II transmembrane topology 
with an extracellular lung homing domain. This prediction was supported by 
FACS analysis of AEG-1 tagged with the Myc epitope at the LHD, which 
indicated extracellular distribution of the C-terminal [2].  The membrane topology 
of the AG-1 protein is controversial however, due to the fact that type Ib topology 
of AEG-1 was also predicted in other studies in which intracellular localization of 
AEG-1 orthologs was confirmed in a number of studies by immunofluorescent 
microscopy [4] [6] [3].  
 The localization of AEG-1 and its function is also an area of much dispute. 
Britt et al. described AEG-1 as a protein localized to tight junctions in polarized 
rat and human prostate epithelial cells and by immunofluorescence LYRIC 
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showed co-localization with the tight junction protein ZO-1 [4]. In the same study 
it was shown that while LYRIC was localized in the tight junctions of normal rat 
hepatocytes, AS30D-rat hepatoma cells as well as human 293T cells 
overexpressing LYRIC showed perinuclear localized of the LYRIC protein. Peri-
nulcear localization of the protein cloned as 3d3/lyric was also reported by 
Sutherland and colleagues who also reported detection in the endoplasmic 
reticulum (ER), nucleus and nucleolus of HeLa and human fibrosarcoma cells [3]. 
On the other hand, Brown and Ruoslahti, from the Burnham Institute, identified 
Metadherin as a cell surface protein in mouse breast cancer cells and HEK293T 
cells overexpressing Metadherin [2]. It has been hypothesized that the large C-
terminal domain of the protein is displayed outside of the cell thus facilitating 
homing of breast cancer cells to the lung and promotes metastasis. In tissue 
sections of human breast cancer, the protein was localized predominantly in the 
cytoplasm [9]. However, a recent study from China analyzing 225 breast cancer 
patients showed increased expression of the protein with the progression of the 
disease and AEG-1 expression inversely correlated with patient survival [10]. 
Interestingly, in this study, the metastatic tumors showed more nuclear staining 
[10]. Our group has also also observed a similar phenomenon in melanoma 
patient samples showing higher nuclear staining in metastatic disease. In human 
HCC cells, unpermeabilized cellular conditions result in detection of the AEG-1 
protein exclusively on the cell surface however upon permeabilization of cells, 
AEG-1 can be detected both in the cytoplasm as well as in the nucleus. In 
malignant glioma cells, strong nuclear staining of AEG-1 is observed and in both 
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HeLa cells and malignant glioma cells TNF-α treatment results in nuclear 
translocation of the AEG-1 protein where it interacts with the p65 subunit of NF-
κB and the transcription co-activator CBP [11] [12]. Nuclear access is attributed 
to the three putative nuclear localization signals (NLS) (Fig. 1.2) identified 
between amino acids 79 to 91 (NLS-1), 432 to 451 (NLS-2), and 561 to 580 
(NLS-3) [3]. Each of the three putative NLSs appears to function differently in the 
nuclear localization of AEG-1. NLS-3 is thought to be the primary determinant of 
AEG-1 nuclear localization, while NLS-1 is said to regulate nucleolar localization. 
AEG-1 is monoubiquitinated at NLS 2 and it is believed that this ubiquitination is 
responsible for trapping AEG-1 in the cytoplasmic compartment a process 
thought to be responsible for the cytoplasmic distribution of AEG-1 occurring in 
cancer cells [13].  Based on the available data, it is apparent that AEG-1 might 
be localized in membrane tight junctions, the cytoplasm, endoplasmic reticulum 
or the nucleus in a cell type and cell status dependent manner. The role of AEG-
1 in each sub cellular compartment and the specific mechanisms facilitating the 
translocation of AEG-1 requires further investigation.  
 In an attempt to gain insights into the potential physiological role of AEG-1 
in normal development, Jeon and colleagues examined the expression pattern of 
AEG-1 in mouse embryonic tissues which are similar to humans in that 
progenitor cells exist for differentiation and cell proliferation for tissue and organ 
formation [14]. In this study the expression pattern of AEG-1 during mouse 
embryo development from stage E8.5 through E18.5 was analyzed. Quantitative 
real-time PCR was used to analyze mRNAs extracted from whole wild-type 
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mouse embryos at E8.5, E9.5 and E10.5 in varying degrees at each of the three 
stages. Peak expression of AEG-1 was identified at E10.5. Whole mount 
immunohistochemistry was also performed to assess the spatial and temporal 
expression pattern of AEG-1 in E9.5 and E10.5 embryos. AEG-1 expression was 
detected in mid-to-hindbrain, fronto-nasal processes, limbs, and pharyngeal 
arches in the early developmental period E9.5–10.5 suggesting that AEG-1 
expression plays a pertinent role in progenitor cell differentiation and/or 
proliferation of early embryos. Expression was increased in the brain, olfactory 
and skeletal systems, skin, hair follicles, and the liver at specific stages during 
E12.5–18.5 indicate a potential involvement of AEG-1 in normal cell proliferation 
during mouse embryonic development. The consistent AEG-1 expression 
observed through all developmental stages of actively proliferating cells and 
tissue like liver, skin and hair follicles combined with co-localization of AEG-1 and 
Ki-67 at the single cell level suggested that AEG-1 expression may be essential 
to actively proliferating cells and tissues that have a strong regenerative ability.  
 Analysis of adult human multiple tissue Northern blots (ClonTech) 
demonstrated that AEG-1 mRNA is ubiquitously expressed at varying levels in all 
organs [6]. Kang and colleagues did however report higher AEG-1 expression in 
two categories of organs, muscle-dominating organs such as skeletal muscle, 
heart, tongue and small intestine, and endocrine glands including thyroid and 
adrenal gland suggesting a possible role of AEG-1 in calcium-associated 
processes in adult tissue however this potential role has not been studied further.  
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Figure	  1.2	  Motifs	  present	  in	  AEG-­‐1	  protein.	  The	  numbers	  represent	  amino	  acid	  
positions.	  TMD:	  transmembrane	  domain.	  NLS:	  putative	  nuclear	  localization	  signal. 
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III. Factors Affecting Astrocyte Elevated Gene-1 Expression 
 
A. Ha-Ras Regulates Expression of Astrocyte Elevated Gene-1 
 
 AEG-1 is a downstream target of Ha-ras an oncogenic protein crucial in 
cellular transformation, tumor progression, and metastasis. The effect of 
oncogenic Ha-ras on AEG-1 expression was examined in a 2006 study [15].  
Specifically examined was the effect of Ha-ras overexpression on the 
transcription and translation of AEG-1. Transient transfection of a Ha-ras 
expression plasmid into immortalized adult human astrocytes (THV cells) 
resulted in significant induction of AEG-1 protein. It was also shown that this 
AEG-1 protein accumulation was associated with an increase in AEG-1 specific 
mRNA expression, which was caused by enhanced transcription. Collectively this 
data suggests that Ha-ras-mediated AEG-1 induction is regulated at the 
transcriptional level rather than by protein stabilization. Furthermore, promoter 
analysis of AEG-1 showed that c-Myc binding at two specific E-box elements was 
critical for Ha-ras-mediated AEG-1 promoter activation as well as for basal 
promoter activity. Treatment of cells with the PI3K inhibitor, LY294002 
significantly attenuated Ha-ras-mediated AEG-1 promoter activation further 
suggesting that this effect was mediated through the PI3K signaling pathway 
[15]. This study also identified positive and negative regulatory regions within the 
AEG-1 promoter. Two E-box elements found within the positive regulatory region 
were found to be essential for both basal and Ras-induced promoter activity. 
Additional putative transcription factor binding sites for Sp1, E-box element, 
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CREB, and Ets-2 were found within the positive regulatory region, and the 
negative regulatory region held potential RAR-α and YY1 binding sites whose 
functional relevance require further investigation.  
 
B. Astrocyte Elevated Gene-1 Induction by Pro-inflammatory Factors 
 
 AEG-1 was initially identified as neuropathology-associated gene in 
primary human fetal astrocytes (PHFA) inducible by both HIV-1 and TNF-α [1]. 
Subsequent studies have proven that TNF-α not only induces AEG-1 expression 
but also stimulates nuclear translocation of AEG-1 where its interaction with p65 
results in activation [12]. Similarly Khuda et al has shown that the Gram-negative 
bacterial component lipopolysaccharide (LPS) is also a potent activator of AEG-1 
in human promonocytic cells [16]. In that study LPS treatment of U937-	  human 
promonocytic cells induced AEG-1 by activation of the NF-κB pathway and 
conversely, AEG-1 activation was shown to be required for LPS-induced NF-κB 
activation. Furthermore, LPS treatment also induced TNF-α and prostaglandin E2 
(PGE2) production in these cells via NF-κB activation [16]. This data confounds 
previous reports that a relationship exists between AEG-1 and NF-κB primarily in 
response to inflammatory cues further suggesting that AEG-1 may play a role in 
the inflammatory response as a regulatory molecule for the control of TLR4 
(LPS)-mediated gene expression. Taken together, these studies suggest a 
possible positive feedback loop between AEG-1 and NF-κB.  
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C. Micro RNA Regulation of Astrocyte Elevated Gene-1 Expression 
 
 Micro RNAs (MiRNAs) are a class of endogenous small noncoding RNAs 
derived from distinctive hairpin precursors in plants and animals [17]. These 
endogenous RNAs pair to sites in mRNAs, typically in their 3’ untranslated region 
(3’UTR) to direct post-transcriptional repression. A single miRNA may target 
multiple genes, and a single gene may be regulated by multiple miRNAs [18]. At 
least one-third of all human genes are predicted to be miRNA targets and indeed 
several miRNAs have been identified which target and modulate AEG-1 
expression. MiR-375 is perhaps the most well documented example of this. 
Initially MiR-375 was identified as a specific regulator of pancreatic islet cell 
function and was found to regulate insulin secretion [19]. Further studies 
revealed miR-375 to be a multifunctional miRNA participating in multiple aspects 
of islet cell development as well as glucose homeostasis. Most recently studies 
have shown that miR-375 is significantly downregulated in multiple types of 
cancer [20] . TargetScan-the online software provided by MIT for prediction of 
miRNA targets has identified AEG-1 as a putative target of miR-375 and indeed 
studies done to examine the functional relevance of these in silico predictions 
have corroborated this prediction. In one study, miR-375 was shown to directly 
aim at its predicted binding site in AEG-1s 3’ untranslated region (3’UTR) leading 
to the suppression of luciferase expression of a pLUC-AEG-1 construct, however 
no such effect was seen with use of a control construct. Furthermore 
overexpression of miR-375 in HCC-positive HepG2 cells was shown to greatly 
reduce AEG-1 mRNA and protein levels while inhibition of miR-375 led to 
	   	   14	  
	  
enhanced AEG-1 mRNA and protein expression in normal primary human 
hepatocytes further corroborating the luciferace data [21].  In separate study 
focused on the functional significance of miR-375 in cancer cells and 
identification of miR-375-regulated novel cancer networks in head and neck 
squamous cell carcinoma (HNSCC) a genome-wide gene expression analysis 
miR-375 was performed to search for miR-375-regulated molecular targets. This 
screen identified AEG-1 as a target of miR-375 in SAS and FaDu-head and neck 
squamous cell carcinoma HNSCC cell lines. It was shown that the aberrant 
downregulation of miR-375 in these cancer cells was correlated to the AEG-1 
overexpression seen in HNSCC patients [22]. Restoration of miR-375 resulted in 
a decrease in AEG-1 protein levels as well as significant inhibition of cell 
proliferation and induction of cell apoptosis in the cell lines used.  
In addition to miR-375 other micro RNAs have been shown to directly 
target AEG-1 expression. Under normal conditions miR-26a protects normal liver 
tissue from inflammation [23]. Aberrant downregulation of miR-26a has however 
been linked to increased metastasis in breast cancer patients and decreased 
survival rates in HCC patients [24] [23]. In a recent study, overexpression of miR-
26a was shown to initiate breast tumor cell apoptosis by targeting MTDH [24].  
MiR-137 expression has also been inversely correlated with AEG-1 levels. 
In ovarian cancer patient specimens miR-137 was shown to downregulate AEG-1 
expression through interaction at AEG-1s 3’UTR [25]. In this study 
overexpression of miR-137 was shown to repress AEG-1 expression in ovarian 
cancer cells lines and also significantly inhibit cell growth and colony formation 
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activity. Restoring an AEG-1 transcript without the 3’UTR rescued miR-137-
induced cell growth and colony formation inhibition suggesting that that AEG-1 
may in fact be a functional target of miR-137 [25].  
AEG-1 was also identified as a target of miR-136 in glioma cells. In this 
study miR-136 overexpression in glioma cells was shown to decrease AEG-1 
expression, increase the apoptotic rate of glioma cells and sensitized cells to 
Cisplatin induced death [26].  
 
IV. Relevant Astrocyte Elevated Gene-1 Protein Interactions 
 
A. Nuclear Factor Kappa-Light-Chain-Enhancer of Activated B Cells  
 
 Although AEG-1 has no DNA binding domains and has not been shown to 
directly bind to DNA, it does play a role in modulation of transcription and 
translation via numerous protein interactions such as with Nuclear Factor Kappa-
Light-Chain-Enhancer of Activated B Cells (NF-κB). NF-κB is transcription factor 
regulating the expression of genes involved in a wide variety of physiological 
processes ranging from regulation of cell growth and cell survival to cell 
adhesion, inflammation and differentiation. This very critical factor facilitates cell 
responsiveness to a large number of extracellular stimuli. NF-κB has also been 
identified as a critical component of numerous essential systemic functions 
including inflammatory cascades, innate immune responses, adaptive immune 
responses, secondary lymphoid organ development and osteoclastogenesis. 
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In a 2006 study Emdad et al described the nuclear translocation of both 
AEG-1 and the p65 subunit of the NF-κB protein complex following TNF-α 
treatment in HeLa cells [12]. This was one of the first studies to show that these 
two proteins physically interacted, suggesting a potential mechanism by which 
AEG-1 could activate NF-κB. AEG-1 was shown to translocate to the nucleus of 
TNF-α treated cells where it activated NF-κB by specific interaction at the region -
a.a. 101–205. Furthermore AEG-1s N-terminal (specifically a.a. 1–71) was 
identified as the site of interaction with NF-κB, which was also shown to be 
critical for NF-κB activation [11]. It is important to note that the interaction 
between AEG-1 and NF-κB is not seen under basal cellular conditions in which 
AEG-1 localized both in the cytoplasm and in the perinuclear region. However, 
upon upregulation of AEG-1 following TNF-α treatment, AEG-1 was shown to 
facilitate IκBα degradation resulting in an increase in NF-κB DNA binding activity 
and NF-κB promoter activity [11].  In addition to this, gene array analysis showed 
that ectopic expression of AEG-1 by adenovirus (Ad.AEG-1) infection in HeLa 
cells resulted in marked upregulation of numerous NF-κB-responsive cell 
adhesion molecules. Induced molecules included CAM-2 and ICAM-3, factors 
frequently overexpressed in B-cell chronic lymphocytic leukemia [27], selectin E, 
and selectin P ligand, known to regulate the adherence and metastasis of a 
cancer cells to endothelium [28] [29] and TLR4 which has been implicated in 
tumor cell immune evasion [30]. Ad.AEG-1 infection of HeLa cells also resulted in 
marked upregulation of a number of cytokines including IL-8 [12]. This was later 
corroborated with evidence showing that AEG-1 is able to facilitate the binding of 
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NF-κB to the cyclic AMP-response element binding protein (CREB)-binding 
protein (CBP) complex on the IL-8 promoter in inflammatory responses by 
interacting with CBP [11]. Recently Khuda and colleagues showed that AEG-1 
was induced via the NF-κB pathway in U937 human promonocytic cells following 
lipopolysaccharide (LPS) stimulation. Conversely, shRNA mediated knockdown 
of AEG-1 in the human breast cancer cells (MDA-MB-231) was shown to abolish 
NF-κB activation by LPS and effectively blocked LPS-induced IL-8 and MMP9 
production [16, 31]. It is clear that the interaction between AEG-1 and NF-κB is 
an important component of inflammatory cascades however it may also be 
surmised that innate immune responses, adaptive immune responses, secondary 
lymphoid organ development and osteoclastogenesis, other processes regulated 
by NF-κB may also be impacted by AEG-1 expression and activity.  
 
B. Sumoylated Promyelocytic Leukemia Zinc Finger Protein and C-Myc 
 
 The interaction between AEG-1 and the sumoylated promyelocytic 
leukemia zinc finger protein (PLZF) was initially identified by yeast two-
hybridization (Y2H) screening methods. PLZF was shown to interact with the 
AEG-1 protein at two regions (a.a. 1–285 and 487–582) and a.a. 322–404 was 
shown to be the site important site for this interaction on the PLZF protein [31]. 
The PLZF protein is a transcriptional repressor that binds to the promoter of 
various genes including cyclin A2, interleukin-3 receptor (IL-3Rα) and the proto-
oncogene c-myc. PLZF also contributes to the regulation of cell growth, death, 
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and differentiation by functioning as both a proapoptotic and an antiapoptotic 
factor [32] [33]. Co-expression of AEG-1 with PLZF results in a substantial 
increase in c-Myc transcript level. Chromatin immunoprecipitation (ChIP) 
techniques revealed that AEG-1 suppresses the binding of the PLZF to the c-Myc 
promoter, thus causing increased transcription of c-Myc. MYC expression is 
frequently deregulated in tumor cells by chromosomal translocation or gene 
amplification. This deregulation of c-myc is thought to induce a metabolic 
adaptation wherein tumor cells alter their metabolism in order to support 
accelerated growth and survival. As an oncoprotein MYC promotes 
tumorigenesis by inappropriate regulation of transcriptional programs resulting in 
uncontrolled cell proliferation, independence of growth factors and genomic 
instability [34]. The interaction of AEG-1 with PLZF prevents the recruitment of 
PLZF to the c-Myc promoter, ultimately leading to upregulation of c-Myc 
transcription. This represents another way in which AEG-1 functions as a 
regulator of transcription through protein-protein interaction and also takes part in 
the promotion of tumorigenesis.  
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C. Staphylococcal Nuclease Tudor Domain Containing 1 and the RNA-Induced 
Silencing Complex 
 
 Staphylococcal nuclease tudor domain containing 1 (SND1) was first 
identified as a transcriptional co-activator for Epstein–Barr virus nuclear antigen 2 
and has since been found to be a multifunctional protein with reported roles in 
transcriptional activation, RNA editing, the apoptotic cascade, regulation of 
spliceosome activity and formation of the RNA-induced silencing complex [35] 
[36] [37] [38] [39] [40]. The interaction between AEG-1 and SND1 was first 
identified by means of an unbiased, mass spectrometry based screen for MTDH-
interacting partners [41].  In a recent study AEG-1 was identified as a component 
of the RNA-induced silencing complex (RISC) [40]. This interaction was 
determined based on AEG-1s interaction with both Argonaute 2 (Ago2), the 
major nuclease of the RISC and SND1 also known to function as a nuclease in 
the RISC [39]. Coimmunoprecipitation analysis using lysates from HCC cell lines 
demonstrated an interaction between AEG-1 and both SND1 and Ago2. This 
data was supported by double immunofluorescence studies demonstrating the 
ability of AEG-1 to co localize with both Ago2 and SND1. In this study AEG-1was 
shown to interact with SND1 in the cytoplasm to facilitate RISC activity. 
Furthermore it was demonstrated that both AEG-1 and SND1 are required for 
optimum RISC activity facilitating small interfering RNA (siRNA) and micro RNA 
(miRNA)-mediated silencing of luciferase reporter genes. AEG-1 overexpression 
and binding to SND1 was also shown to aid oncomiR-mediated degradation of 
tumor-suppressor messenger RNAs. Potential targets of this increased RISC 
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degradation included tumor suppressor mRNAs such as PTEN, CDKN1C, 
CDKN1A, p21 and TGFBR2. Indeed expression of all of these targets was shown 
to be downregulated in response to overexpression of AEG-1 or SND1 and 
upregulated, upon knockdown of AEG-1 or SND1 [39]. The described study 
spoke specifically to the impact of the of AEG-1-SND1 interaction on the 
expression tumor suppressor genes however, SND1 has been identified as an 
essential component of many aspects of gene expression. For example SND1 
has also been shown to associate with the U5 small nuclear ribonucleoprotein 
component of the spliceosome and enhance spliceosome assembly and activity 
[42] [43]. In contrast, the role of SND1 as a coactivator and transcriptional 
activator have also been well studied. Numerous studies also show that AEG-1 
expression correlated directly to SND1 expression [39] [41] [44]. This suggests 
that the two may in fact interact to modulate the expression of a wide range of 
genes ultimately molding genetic diversity in eukaryotes not only through 
modulation of RISC activity but perhaps also by manipulation of transcription 
and/or spliceosome machinery assembly. 
 
D. Retinoid X Receptor 
 
  One of the more intriguing structural features of the AEG-1 protein is the 
“LXXLL” (L, leucine; X, any amino acid) motif located at a.a. 21-25 of its NH2-
terminal region (Fig 1.2). The LXXLL sequence was originally identified in 
proteins that bind the activation function-2 (AF-2) region of nuclear receptor 
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ligand-binding domains (LBDs) [45].  These conserved motifs were shown to 
have a key role in nuclear-receptor regulation with many nuclear-receptor-binding 
proteins and co-repressors capable of interacting with and modulating the activity 
of liganded nuclear receptors (NR) [46]. While the presence of the LXXLL 
sequence is not exclusive to molecules involved in regulation of NR activity it is a 
protein-recognition motif widely used in transcriptional regulation. No previous 
reports have defined the functional relevance this very important regulatory 
sequence in AEG-1. Our group has recently put forth efforts to investigate the 
biological relevance of this motif to AEG-1 function. To this end yeast 2 
hybridization (Y2H) screening of a human liver cDNA library was performed using 
the NH2-terminal (a.a.1-57) of AEG-1 as bait. Interestingly this screen provided 
evidence of an interaction of between AEG-1 and the Retinoid X Receptor β 
(RXRβ). RXR is an essential member of the steroid/thyroid hormone super family 
of nuclear receptors and is a master regulator of a plethora of physiological 
processes functioning as a transcription factor with roles in development, cell 
differentiation, metabolism, and cell death. The association between 
RXRβ/RXRα and AEG-1 was confirmed by co-immunoprecipitation (Co-IP) 
assays performed using human HCC cell lines. Mutation of AEG-1s LXXLL motif 
nullified this RXR-AEG-1 association solidifying the importance of the LXXL motif 
to this interaction. Conversely, deletion of the C-terminal ligand-binding/AF-2 
domain (LBD) of RXRα, but not the N-terminal AF-1/DNA binding domain (DBD) 
also abolished the RXR-AEG-1 interaction suggesting that the LBD is the site of 
AEG-1 interaction. This data provided evidence in support of the hypothesis that 
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AEG-1s LXXLL motif is a functional domain and a site of interaction with RXR. 
RXR plays a major role in regulating genes controlling cell proliferation and 
differentiation in the context of its heterodimeric binding with the RAR. 
Interestingly inhibition of basal and ligand-dependent RARE activity was also 
observed in both AEG-1 overexpressing cancer cells and primary AEG-1 
transgenic (Alb/AEG-1) hepatocytes while RARE activity was amplified in AEG-
1KO mouse hepatocytes and in cancer cells following siRNA directed AEG-1 
knockdown suggesting that AEG-1 expression impacts RXR-binding partner 
activity. Even more compellingly that study showed that AEG-1 activation of ERK 
induced RXR phosphorylation leading to its functional inactivation and 
attenuation of ligand-dependent transactivation [47]. Taken together, these 
findings show for the first time that that AEG-1 interacts with RXRs AF-2 ligand-
binding domain via its own LXXLL motif.  This interaction modulates nuclear 
receptor/co-activator binding activity and subsequently impacts RXR activation. 
In the absence of ligand, RXR is bound to hormone response elements 
complexes with corepressor proteins. The binding of agonistic ligands to RXR 
results in dissociation of corepressors and recruitment of coactivator proteins 
possessing distinct LXXLL motifs. The negative regulation of RXR by AEG-1 
suggests a potential mechanism by which AEG-1 may impact the maintenance of 
RXR homeostasis.  By competing for coactivator binding, AEG-1 may impact 
RXR activation and the transcription of RXR target genes. The existence of 
putative transcription factor binding sites for RAR-α within AEG-1s negative 
regulatory region has previously documented, [15] combined with the data from 
	   	   23	  
	  
this most recent study there is reason to suspect that AEG-1 may be part of a 
feedback mechanism regulating RXR and RAR binding. This being said, it may 
be of interest to further explore the role of AEG-1 in the maintenance of RXR 
homeostasis. 
 
E. Additional Interactions and Regulatory Mechanisms 
 
 The AEG-1 molecule possesses a number of interesting domains that may 
explain some of its proposed functions. Evidence that AEG-1 aids in the homing 
of metastatic breast cancer cells to the lung vasculature is supported by the 
presence of a putative lung-homing domain (LHD) (amino acid region 378–440) 
[2, 48]. The molecule also contains a C-terminal ‘435-GALPTGKS-442’ sequence 
predicted to as a potential ATP/GTP binding (Sutherland et al., 2004). There are 
also a number of interesting putative post-translational modification residues and 
regulatory residues within the AEG-1 protein including potential sites of 
phosphorylation, ubiquitination and acetylation [49]. The relevance of most of 
these sites have yet to be explored but evidence exists that suggests that at least 
some of these modifications impact protein function and localization. AEG-1 
protein is detected as a 75-kDa band by Western blot analysis although its 
predicted molecular weight is 64 kDa. This gap has been attributed to 
monoubiquitination of lysines within AEG-1s NLS-2 region. Additionally, cell 
fractionation showed that ubiquitinylated LYRIC/AEG-1 is almost exclusively 
cytoplasmic indicating that this type of modification is also responsible for cellular 
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localization of the protein [31]. Furthermore, reduction of AEG-1 ubiquitination 
has recently been shown to both alter its sub-cellular distribution and impair the 
interaction between AEG-1and p65/NFκB [50]. The biological significance of 
these modifications have not yet been determined but certainly warrants 
additional research efforts. 
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Chapter Two-Astrocyte Elevated Gene-1 Regulates Lipid Metabolism 
 
I. Introduction 
The role of Astrocyte Elevated Gene-1 as an oncogene is well-established [9, 51-
53]. AEG-1 plays a crucial role in regulating tumor cell proliferation, invasion and 
metastasis [2, 9, 51, 54], and positively contributes to tumor-associated 
angiogenesis, chemoresistance and protection from apoptosis [52, 55-57]. 
However, the physiological function of AEG-1 is still not known. The AEG-1 gene 
is present only in vertebrates, in which the protein is highly conserved, 
suggesting that AEG-1 evolved to perform specific functions in higher organisms 
[5]. Analysis of AEG-1 expression during mouse development demonstrated 
AEG-1 expression in mid-to-hindbrain, fronto-nasal processes, limbs and 
pharyngeal arches in the early development period from E8.5 to E9.5 [14]. At 
stages of E12.5 to E18.5 AEG-1 expression was detected in the brain, the 
olfactory and skeletal systems, skin and liver. Co-localization of AEG-1 
expression was observed with the proliferation marker Ki-67 and it was 
hypothesized that AEG-1 might play a role in normal mouse development in the 
context of cell proliferation and differentiation [14].  
 We recently identified a novel interaction between AEG-1 and Retinoid X 
Receptor (RXR), a transcription factor functioning as an obligate heterodimer 
partner of diverse nuclear receptors mediating the action of hormones, vitamins 
and lipids [54, 58, 59]. AEG-1 interacts with RXR via a ‘LXXLL’ motif [45] and this 
interaction was found to interfere with co-activator recruitment and inhibit RXR-
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mediated transcriptional regulation by its heterodimer partners. The current study 
unravels a novel physiological function of AEG-1 in lipid homeostasis by 
analyzing an AEG-1 knockout (AEG-1KO) mouse.  Although AEG-1KO mice 
were viable and fertile, they were significantly leaner, had prominently less body 
fat and lived significantly longer when compared to wild type (WT) mice. When 
maintained on a high fat and cholesterol diet (HFD), WT mice rapidly gained 
weight while AEG-1KO mice did not gain weight at all. This phenotype of AEG-
1KO mice was due to decreased fat absorption from the intestines because of 
increased activity of Liver X Receptor (LXR) and Peroxisome Proliferator 
Activated Receptor (PPAR)-α in enterocytes. LXR and PPARα are both 
heterodimer binding partners of RXR, in the intestines. LXR is a nuclear receptor 
which functions as a cholesterol sensor and regulator of transcription of a set of 
genes associated with cholesterol absorption, transport, efflux and excretion. 
Thus LXR is critical for the control of lipid homeostasis and response to 
physiological concentrations of sterols [60] [61]. There are two LXR isoforms, 
LXRα and LXRβ, both of which form obligate heterodimers with RXR. In 
enterocytes, activation of LXR inhibits cholesterol absorption by downregulating 
cholesterol transporter Npc1l1 and upregulating cholesterol efflux proteins, 
Abca1, Abcg5 and Abcg8 [62]. PPARα, a subtype of the PPAR superfamily, also 
interacts with the retinoid X receptor to function as a transcription factor to induce 
the expression of a series of genes involved in fatty acid transport and 
mitochondrial fatty acid oxidation [63]. Activation of PPARα in the enterocytes 
promotes β-oxidation of absorbed fatty acids thereby downregulating fatty acid 
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absorption into the circulation [64]. Products of cholesterol metabolism, such as 
the oxysterols 24(S)-hydroxycholesterol, 22(R)-hydroxycholesterol, 24(S), 25-
epoxycholesterol and 27-hydroxycholesterol, function as ligands for LXR while 
fatty acids and fatty acid derivatives are endogenous ligands for PPARα [60, 65]. 
A high fat diet provides ligands to both LXR and PPARα thereby accentuating 
this effect and providing a potential mechanism to explain the almost complete 
inhibition of fat absorption by AEG-1KO mice placed on a HFD. The studies 
described in this chapter reveal a novel role of AEG-1 in regulating nuclear 
receptors regulating lipid metabolism. By regulating LXR and PPAR-α function 
AEG-1 might be a key component of lipid homeostasis. The observed resistance 
of AEG-1KO mice to HFD suggests that AEG-1 may also significantly modulate 
the effects of high fat diet, and thereby function as a unique determinant of 
obesity perhaps also playing a role in obesity-associated diseases. 
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II. Materials and Methods 
Generation of AEG-1 Knockout (AEG-1KO) mice: 
 To generate AEG-1KO mice, an AEG-1KO targeting vector was 
constructed.  Contiguous AEG-1 genomic regions were generated by high-fidelity 
PCR from 129/SvEv embryonic stem (ES) cell DNA and sequentially cloned into 
the NDTV targeting vector, which contains both a floxed neomycin 
phosphotransferase (neo) cassette for positive selection of homologous 
recombinants with the neomycin analog G418, and a diphtheria toxin A (DT-A) 
cassette for negative selection of non-homologous recombinants.  The final AEG-
1KO targeting vector possesses a 5’ homology arm containing both the AEG-
1promoter and exon 1, and a 3’ homology arm containing part of intron 1.  The 5’ 
arm also has a loxP site inserted just 5’ of a 257-bp region of homology (71%) 
between the human and mouse promoters.  
 The AEG-1KO targeting vector was linearized with Nhe I and 
electroporated into 129/SvEv ES cells.  ES cell clones resistant to G418 were 
screened for homologous recombination by Southern blot analysis using both 3’-
flanking genomic and neo cassette probes.  Retention of the introduced loxP site 
in homologous recombinants was verified by PCR using a 5’-flanking primer in 
combination with a unique loxP primer.  Two ES cell clones possessing the 
targeted AEG-1KO allele were injected into C57BL/6 blastocysts, which were 
then implanted into pseudopregnant CD-1 recipients.  To generate the final 
conventional AEG-1KO alleles, chimeric males were bred to homozygous EIIa-
cre females (Jackson Laboratory, stock number 003724).  Agouti offspring were 
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screened for the conventional KO allele with a 3-primer PCR protocol using a 
common anti-sense primer (5’-CTTGAGATAGACATCTCTCTCTAC-3’) in 
combination with two sense primers: (5’-GAAGAATCTCAGAAGCGAGGAGC-3’)  
and (5’-GCTTAGCAAGAGTAGCTTATTACG-3’), specific for the wild-type and 
conventional KO alleles and generating PCR products of 397 bp and 577 bp, 
respectively.   
All animal studies were approved by the Institutional Animal Care and Use 
Committee at Virginia Commonwealth University, and were conducted in 
accordance with the Animal Welfare Act, the PHS Policy on Humane Care and 
Use of Laboratory Animals, and the U.S. Government Principles for the 
Utilization and Care of Vertebrate Animals Used in Testing, Research, and 
Training.  
AEG-1KO mice were viable and fertile, although litter sizes were very 
small (1-2 pups per litter). Further, even litters generated by crossing AEG-1+/- 
breeding pairs were very small (2-3 pups per litter), which precluded generating 
large numbers of WT and AEG-1KO mice as littermates. Therefore, the majority 
of the experiments were carried out with age-matched mice generated by 
breeding WT and AEG-1KO mice separately. However, it should be noted that 
the same phenotypes (as described in the next sections) were observed in AEG-
1KO mice generated from AEG-1+/- X AEG-1+/- matings as from AEG-1KO X 
AEG-1KO matings. Additionally, the experiments described here were performed 
with mice on a C57BL/6:129/Sv background. However, we have backcrossed the 
line to C57BL/6 for 10 generations and obtained similar results for both the WT 
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and AEG-1KO mice on the C57BL/6 background as on the C57BL/6:129/Sv 
background. Thus our findings are not restricted to strains or littermates status. 
Measurement of food consumption and body weight: 
 Measured amount of food was given to 4-weeks old age-matched WT and 
AEG-1KO mice (n=8/group) housed in individual cages. Amount of food 
consumed per week was determined by measuring the leftover food. Body 
weight was also measured weekly. The experiment was performed for 12 weeks. 
Food consumption was calculated by the amount of food (in gm) consumed per 
gm of body weight.    
 Mice were fed a regular chow diet. For high fat diet (HFD) experiments, 8 
weeks old mice were fed high fat and cholesterol containing diet (Harlan; TD. 
88137) for 5 weeks. 
MRI of total body fat mapping: 
Male WT and AEG-1KO mice at 12 weeks of age were used (n=6/group). 
Using a Bruker-Biospin Biospec console and a 7 Tesla, 30 cm free bore magnet 
(Bruker Biospin, USA), T2 weighted multi-slice spin echo images with and 
without fat suppression were acquired, covering the entire body from the base of 
skull to the tail, with a field of view of 4 x 4 cm and 256 x 256 matrix size. Animals 
were anesthetized with isoflurane during preparation (4%) and imaging (1%). The 
imaging parameters used were: repetition time (TR) of 6.5 s, time of echo (TE) of 
56 ms. The resultant 2D images were exported and analyzed using ImageJ 
software (NIH, Maryland, USA). By subtracting the fat-suppressed images from 
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the non-fat suppressed images fat-only images were produced, which were then 
used for ROI analysis of the fat depots. Multiplying the area of the ROI by slice 
thickness gave the volume. 
Indirect Calorimetry:  
Male WT and AEG-1KO mice at 12 weeks of age were used (n=6/group). 
VCO2, VO2, and respiratory quotient (RQ) were measured using a four chamber 
Columbus Instruments Comprehensive Lab Animal Monitoring System 
CLAMS/Oxymax (Columbus, OH) indirect calorimetry (IDC) machine, which was 
calibrated based on the O2 and CO2 levels of the room dedicated for indirect 
calorimetry only. The mice were acclimated to the IDC room for 1 week prior to 
the experiment. The oxygen consumption is calculated by taking the difference 
between the input oxygen flow and the output oxygen flow. Similarly, the carbon 
dioxide production is calculated by taking the difference between the output and 
input carbon dioxide flows. The calculations are described below: 
VO2 = Vi O2i -Vo O2o     
Vi and Vo are the input and output ventilation rates (LPM)     
O2i and O2o are oxygen fractions at the input and output 
VCO2 = VoCO2o -ViCO2i    
Vi and Vo are the input and output ventilation rates (LPM) 
CO2i and CO2o are carbon dioxide fractions at the input and output 
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The respiratory exchange ratio (RER) is simply the ratio between the 
carbon dioxide production and the oxygen consumption thus the equation is: 
RER = VCO2/VO2. Energy expenditure or Heat is calculated before the 
application of any normalization or correction and, thus, reflect the exact heat of 
the subject. The calorific value (CV) is based on the observed respiratory 
exchange ratio. CV is then used with the observed oxygen consumption (VO2) to 
calculate heat, the equations are: 
Heat = CV × VO2 
CV = 3.815 +1.232 × RER 
Measurement of triglyceride concentrations and synthesis by stable 
isotopes  
The Case Mouse Phenotyping Center (MMPC) measured the triglyceride 
content and newly synthesized triglyceride levels. In order to enrich the body 
water with ~2% 2H, IP injection of labeled water (20 µL • g-1 of body weight of 9 
g/L NaCl in 99% atomic percentage excess 2H2O) was administered to adult 
male mice, and they were returned to their cages and maintained on 5% 2H-
labeled drinking water for 5 d. The mice were sacrificed, and blood and tissue 
samples were collected and flash-frozen in liquid nitrogen. The samples were 
stored at -80°C until analysis. Triglyceride concentrations and de novo 
lipogenesis was determined as previously described [66]. Briefly, triglyceride 
from tissues was isolated, and labeled glycerol and palmitate were analyzed after 
derivatization by mass spectrometry. The 2H-labeled triglyceride covalently linked 
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to glycerol measures the amount of newly synthesized triglyceride, while the 2H-
labeled triglyceride covalently attached to palmitate indicates the amount of new 
palmitate. In mice given 2H2O for 5 d, the contribution of de novo lipogenesis to 
the pool of triglyceride and palmitate was calculated using the following equation: 
% newly made palmitate = [total 2H-labeled palmitate • (2H-labeled body water × 
n)]-1 × 100, where n is the number of exchangeable hydrogens, which is 
assumed to be 22 [67, 68]. 
The percentage of total newly made triglyceride glycerol is calculated using the 
following equation:  
% total newly made triglyceride-glycerol = [2H-labeled triglyceride-glycerol • (2H-
labeled water × n)]-1 × 100, where 2H-labeled triglyceride-glycerol is the M1 
isotopomer, 2H-labeled water is the average amount labeled in a given mouse, 
and n is the exchange factor (experimentally determined from the M2/M1 ratio of 
triglyceride glycerol). We calculated the total triglyceride pool size (µmol/g tissue) 
in the tissues using the following equation: total pool size of triglyceride = [2H-
labeled triglyceride-glycerol • (2H-labeled water × n)]-1 × 100. 
In vivo cholesterol absorption:  
Fecal dual isotope ratio method [69] was used in which WT and AEG-1KO 
mice were gavaged with 0.5 µCi of [14C]-cholesterol and 1 µCi of [3H]-sitostanol 
in 100 µl of soy bean oil. Mice were fed standard chow diet for three days and the 
feces were collected daily. The radioactivity of the pooled fecal samples was 
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determined by a scintillation counter. The percentage of cholesterol absorption 
was calculated as:  
(([14C]/[3H]) dosing mixture - ([14C]/[3H]) feces) / ([14C]/[3H]) dosing mixture X 100. 
In vivo fatty acid absorption:  
WT and AEG-1KO mice were fasted overnight and i.v. injected with 500 
mg/kg Tyloxapol to block serum lipase activity. After 30 min, mice were gavaged 
with fat emulsion containing 10 µCi [3H]triolein. Blood samples were collected 
from tail vein at time 0 and hourly for 4 h. Serum radioactivity was determined by 
a scintillation counter [70]. 
Metabolomic profiling of plasma samples: 
Plasma samples were extracted using ice cold chloroform/methanol (2:1) 
as described [71]. LC-MS analyses were conducted on a Thermo Fisher Q 
Exactive mass spectrometer with on-line separation using a Thermo 
Fisher/Dionex RSLC nano HPLC. HPLC column is Waters Atlantis dC18 (3 µm, 
300 µm x 150 mm) with mobile phase A, acetonitrile/water (40:60) containing 10 
mM ammonium acetate and mobile phase B, acetonitrile/isopropanol (10:90) 
containing 10 mM ammonium acetate. Data-dependent MS/MS scans were 
performed using one full MS scan (m/z 200 – 2000) followed by 6 MS/MS scans 
in the HCD collision cell with a normalized collision energy (NCE) of 35 arbitrary 
units. Both positive and negative ion detection were performed through Q 
Exactive MS at 70,000 resolution (m/z 300). Raw data were acquired under the 
control of Thermo Xcalibur software (Thermo Fisher). Progenesis CoMet 
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(Nonlinear Dynamics) was used to process the raw data files acquired from the Q 
Exactive MS analyses to detect the metabolites that exhibit significant differences 
(p<0.05 in ANOVA analysis) in the intensity among the different groups of plasma 
samples. Peak alignment and integration was performed and the relative 
abundance was generated for each metabolite among different sample types. 
The metabolites were identified with accurate mass through METLIN and Lipid 
Maps databases searching using a 5-ppm mass tolerance and manual 
interpretation of the MS/MS fragment patterns. The comparison with the retention 
times with commercially available standards was also performed for further 
confirmation. The heat map was drawn for significantly different lipids (p<0.05 
and fold change>2) between WT and KO samples. To assist in visualization and 
interpretation of the data, we performed a z-score transformation of the 
abundances for each lipid. 
Immunohistochemistry 
 Immunohistochemistry was performed using formalin-flixed paraffin 
embedded (FFPE) sections as described previously [51]. The sections were 
blocked in PBST using 10% normal goat serum. Primary anti-AEG-1 antibody 
(rabbit polyclonal; 1:800; generated in-house) was diluted in PBST containing 5% 
normal goat serum. Secondary antibody was diluted in PBST containing 2.5% 
normal goat serum. The signals were developed by avidin-biotin-peroxidase 
complexes with a DAB substrate solution (Vector laboratories). 
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 [18F]-FDG uptake assay 
 Animals were fasted overnight and anesthetized (2% isoflurane in 
Oxygen) under warm conditions for about 10 minutes before the intravenous 
injection of 2-deoxy-2-[18F]Fluoro-D-Glucose (FDG), which was obtained from 
IBA Molecular Inc., (Sterling, VA). Approximately 300 µCi of FDG (11.5±0.6 MBq) 
was injected via tail vein and animals were maintained under anesthesia in a 
warm chamber to maintain normal body temperature. After 60 minutes of FDG 
uptake animals were positioned in the Inveon Preclinical System (Siemens 
Healthcare, PA) and PET data was acquired for 20 minutes with no attenuation 
correction. A CT scan was also acquired for anatomical reference. The PET 
images were processed using manufacturer recommended calibration 
procedures using a phantom of known volume and activity acquired prior to the 
study. OSEM3D-MAP reconstructions were done using Inveon Acquisition 
Workplace 1.5 (Siemens Healthcare, PA) and were used for region-of-interest 
(ROI) analysis in the Inveon Research Workplace 4.1 (Siemens Healthcare, PA). 
The percent injected dose/gram of tissue (%ID/g) values were calculated after 
appropriate decay corrections using the formula , where Ct 
was the concentration of radiotracer in the tissue (MBq/cc), which was obtained 
from the PET images after ROI analysis. Statistical comparisons were made 
using Student’s t-test; p < 0.05 was considered significant.  
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Primary hepatocyte culture and transfection assays:  
Primary mouse hepatocytes were isolated as described [54] and were 
plated on collagen-coated dishes (BD BioCoat collagen type I, BD Biosciences) 
and cultured in Williams E medium (SIGMA) containing NaHCO3, L-glutamine, 
insulin (1.5 µM) and dexamethasone (0.1 µM). For transfections, 1X105 
hepatocytes were plated in 24-well collagen coated plates and the next day 
transfected using Promofectin-Hepatocyte transfection reagent in 9:1 ratio of 
firefly luciferase reporter plasmid containing responsive elements (pGL3.luc, 
pGL3.LXRE.luc, pGL3.PPRE.luc) and renilla luciferase reporter plasmid 
(pGL3.renilla.luc) [54]. After 48 hours, cells were incubated in presence or 
absence of respective ligands (T0901317; 5 µM and CP775146; 2.5 µM) for 
another 24 hours. Luciferase assays were measured using Dual Luciferase 
Reporter Assay kit (Promega) following manufacturer’s protocol and firefly 
luciferase activity was normalized by renilla luciferase activity. Each experiment 
was performed in triplicates and three times to calculate means and standard 
deviations. 
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Total RNA extraction, cDNA preparation and Real time PCR:  
Total RNA was extracted from hepatocytes or mouse tissues using the 
QIAGEN miRNAeasy Mini Kit (QIAGEN, Hilden, Germany). cDNA preparation 
was done using ABI cDNA synthesis kit (Applied Biosystems, Foster City, CA). 
Real-time polymerase chain reaction (RT-PCR) was performed using an ABI 
ViiA7 fast real-time PCR system and Taqman gene expression assays according 
to the manufacturer’s protocol (Applied Biosystems, Foster City, CA).  
Glucose tolerance test (GTT):  
Mice were fasted overnight (16 h) and glucose was injected 
intraperitoneally (1.5 g/kg). Blood samples were collected from tail-tip before and 
at 10, 30, 60, 90 and 120 min after the injection for the measurement of glucose 
with a glucometer.  
Chromatin Immunoprecipitation: 
 12 week old wild-type and AEG-1KO littermates (n=3) were treated with 
the LXR agonist T0901317 (30 µg/gm) by a single oral gavage. 24 hours 
following treatment, the animals were euthanized and livers were immediately 
removed. The Chromatin immunoprecipitation (ChIP) assay was performed using 
a SimpleChIP Plus kit (Cell Signaling Technology, Danvers, MA) according to the 
manufacturer's instruction. Briefly, livers were minced on ice and cross-linking 
was performed by treatment with a 1.5% formaldehyde solution for 20 min at 
room temperature. A solution of 0.125M glycine was added at the end of the 
reaction followed by one wash with cold PBS. Tissue disaggregation was 
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performed using a dounce homogenizer to obtain cells in single cell suspension 
and nuclei were digested with Micrococcal Nuclease. 10 µg of cross-linked 
chromatins were incubated with antibody and allowed to complex overnight at 4 
°C, followed by 2 hour incubation with protein G magnetic beads. The protein G 
magnetic beads immuno-complex was washed four times. DNA/protein 
complexes were eluted from beads and reverse cross-linked at 65 °C. DNA was 
purified and quantitative PCR was performed using Power SYBR Green PCR 
Mastermix (Applied Biosystems Foster City, CA) on the ABI ViiA7 fast real-time 
PCR system according to the manufacturer’s protocol (Applied Biosystems, 
Foster City, CA). PCR efficiencies of primers were examined by standard curve 
of serial-diluted liver extracts input and melting curve functionality. The results 
were analyzed using the software provided with the ABI ViiA7 fast real-time PCR 
system. PCR efficiencies of primers were examined by standard curve of serial-
diluted liver extracts input and melting curve functionality. The primers used were 
Abca1 forward: 5’-GAACGAGCTTTTCCCCTTTC-3’ and Abca1 reverse: 5’-
CCCGGCCTCTGTTTATGTAG-3’. 
Measurement of fatty acid β-oxidation 
Products of fatty acid β-oxidation were measured in fresh liver and small intestine 
homogenates using 14C-palmitate as previously described [72]. 
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III. Results 
 
A. AEG-1KO Mice are Lean and Have a Longer Life Span 
 
  We generated an AEG-1KO mouse in which the promoter region, exon 1 
and part of intron 1 of the AEG-1 gene was deleted using a Cre-loxP system (Fig. 
2.1). The authenticity of AEG-1 knockout was confirmed by Southern blotting, 
genomic PCR, Taqman Q-RT-PCR, Western blot analyses and 
immunohistochemistry (Fig. 2.2 A-D).  
	  
Figure	  2.	  1	  Generation	  of	  the	  AEG-­‐1	  Knockout	  Mouse.	  	  A.	  Targeting	  strategy.	  
Arrowheads	  indicate	  loxP	  sites. 
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Figure	  2.2	  Confirmation	  of	  knockout	  of	  AEG-­‐1	  in	  organs.	  	  	  A.	  Southern	  blotting	  analysis	  
to	  confirm	  genotype	  using	  the	  probe	  shown	  in	  Fig2.1.	  B.	  PCR	  using	  genomic	  DNA.	  For	  A-­‐
B,	  M	  represents	  molecular	  weight	  marker.	  C.	  Western	  blot	  analysis	  for	  AEG-­‐1	  in	  the	  
indicated	  organs.	  D.	  AEG-­‐1	  mRNA	  expression	  in	  different	  organs	  by	  Taqman	  Q-­‐RT-­‐PCR.	  
A.U.:	  arbitrary	  unit.	  F.	  Immunohistochemistry	  for	  AEG-­‐1	  in	  the	  indicated	  organs. 
A
. 
B. 
C. 
D. 
E. 
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 AEG-1KO mice were viable and fertile. At birth no significant difference in 
appearance and body weight were observed between AEG-1KO and WT mice. 
Both WT and KO mice developed normally to full adulthood, indicating that AEG-
1 is likely not involved in developmental regulation. Histological analysis of the 
internal organs of the adult mice also did not reveal any significant and 
noticeable difference between WT and AEG-1KO mice (Fig. 2.3). 
 
 
 
 
	  
	  
	  
	  
	  
Figure	  2.3.	  AEG-­‐1KO	  mice	  do	  not	  show	  histological	  abnormalities.	  H&E	  staining	  of	  
spleen	  and	  kidney	  of	  adult	  WT	  and	  AEG-­‐1KO	  mice.	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   A marked difference in body weight gain was however observed between 
age-matched WT and AEG-1KO mice. At 4 weeks of age, male AEG-1KO mice 
were slightly smaller than their age-matched WT counterparts. However this 
difference was not statistically significant. Weekly monitoring over the next 12 
weeks revealed that the average body weight gain by each WT mouse over that 
period was ~14 gm, wherein the weight gain of AEG-1KO mice was only ~4 gm 
(Fig. 2.4A). During this period, food consumption (gm of food/gm of body weight) 
was similar in both groups (Fig. 2.4B). The substantial difference in body weight 
gain continued with age (Fig. 2.5 A-B) and was more pronounced in male mice 
than in female mice (Fig. 2.5 A-B).  
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Figure	  2.4	  Characterization	  of	  AEG-­‐1KO	  mouse.	  	  A.	  Weekly	  body	  weight	  gain.	  (n	  =	  
8/group).	  B.	  Bi-­‐weekly	  food	  consumption.	  (n	  =	  8/group).	  Data	  represents	  mean	  ±	  SEM.	  
*:	  p<0.05.	  
A. 
B. 
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Figure	  2.5	  Characterization	  of	  AEG-­‐1KO	  mouse.	  A.	  Representative	  photographs	  of	  male	  
WT	  and	  AEG-­‐1-­‐/-­‐	  mice	  at	  6	  and	  15	  months	  of	  age.	  B.	  Average	  body	  weight	  of	  male	  (M)	  
and	  female	  (F)	  mice	  at	  6	  and	  15	  months	  of	  age.	  (N	  =	  12/group).	  For	  graphs,	  data	  
represents	  mean	  ±	  SEM.	  *:	  p<0.05.	  
A. 
B. 
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 MRI analysis demonstrated a significant decrease in subcutaneous, 
intramuscular and visceral fat deposits in 6-month-old AEG-1KO mice as 
compared to WT mice (Fig. 2.6A-B). Both subcutaneous and visceral adipose 
tissue have potential protective and pathogenic effects however excess 
accumulation of either may share similar adipose tissue pathologic processes 
leading to pericardiac and perivascular fat accumulation, as well as fatty 
infiltration of the liver, muscle, pancreas and heart. Indeed our studies show that 
aged (15 months old) WT mice demonstrated steatotic changes in the liver, while 
no such change was observed in AEG-1KO mice (Fig. 2.8B.). Furthermore 
histological evaluation showed that adipocytes in white and brown adipose 
tissues were larger and more abundant in WT mice versus AEG-1KO mice (Fig. 
2.8A). Glucose tolerance was first evaluated to determine if the observed 
phenotype was a result of altered glucose management. No significant difference 
was observed in glucose tolerance, suggesting that insulin signaling is functional 
in AEG-1KO mice (Fig. 2.7). PET-imaging and [18F]-FDG uptake analysis 
methods were also used for the assessment of glucose metabolism but did not 
show any difference between WT and AEG-1KO mice (Table 3.1) suggesting 
that these differences in fat accumulation were not a result of disparities in 
glucose tolerance or peripheral glucose metabolism. A cohort of WT and AEG-
1KO mice were monitored up until 24 months of age. Over this time period, 19 
out of 21 WT mice died, however a significant survival benefit was observed in 
the leaner AEG-1KO mice, of which only 3 of 20 mice expired (Fig. 2.9).  
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Figure	  2.6	  MRI	  Analysis	  of	  mice.	  A.	  Representative	  MRI	  depicting	  areas	  of	  intramuscular	  
(I.M)	  visceral	  (Vis)	  and	  subcutaneous	  (S.C.)	  fat	  deposits.	  B.	  Quantification	  of	  body	  fat	  
distribution	  determined	  by	  MRI.	  (N	  =	  5/group).	  Data	  points	  represent	  individual	  animals;	  
*:	  p<0.05.	  
B. 
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Figure	  2.7	  Glucose	  tolerance	  of	  WT	  and	  AEG-­‐1KO	  mice.	  Blood	  glucose	  was	  measured	  at	  
the	  indicated	  time	  points	  after	  i.p.	  injection	  of	  a	  bolus	  of	  glucose	  in	  fasted	  mice.	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Table	  1	  Glucose	  uptake	  in	  peripheral	  tissues.	  Results	  of	  [18F]-­‐FDG	  uptake	  assay:	  The	  
percent	  injected	  dose/gram	  of	  tissue	  (%ID/g)	  values	  were	  calculated	  after	  appropriate	  
decay	  corrections.	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Figure	  2.8	  Histological	  Evaluation	  of	  Adipose	  and	  Liver	  Tissue.	  A.	  H&E	  staining	  of	  white	  
adipose	  tissue	  (WAT)	  and	  brown	  adipose	  tissue	  (BAT)	  at	  15	  months.	  B.	  H&	  E	  staining	  of	  
WT	  and	  KO	  liver	  sections	  at	  15	  months.	  
A. B. 
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Figure	  2.9	  Aging	  Study.	  Kaplan-­‐Meier	  survival	  curve;	  representing	  WT	  and	  AEG-­‐1KO	  
mouse	  viability	  over	  24	  months.	  (n	  =	  21	  for	  WT	  and	  n	  =20	  for	  AEG-­‐1KO)	  *:	  p<0.05.	  
*	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B. Intestinal fat absorption is inhibited in AEG-1KO mice 
 In the absence of differential glucose tolerance, three potential causative 
factors remained that could result in the profound lack of fat in AEG-1KO mice. 
These factors included: (1) defects in fat synthesis, (2) increased energy 
expenditure (fat burning), and/or (3) decreased fat absorption from the intestine. 
Each of these factors was interrogated individually as part of the characterization 
of the AEG-1KO mice. First to be evaluated was serum total triglyceride (TG) and 
cholesterol levels. Both of which were significantly lower in AEG-1KO compared 
to WT mice (Fig. 2.10A). Interestingly, although the total TG level was low in 
AEG-1KO mice, a comprehensive serum lipidomic analysis revealed significantly 
higher levels of triglycerides (TG) containing long-chain fatty acids in AEG-1KO 
mice as compared to age-matched WT mice (Fig. 2.11). Levels of newly 
synthesized TG and palmitate in liver and muscle of WT and AEG-1KO mice 
were also found to be similar in between WT and AEG-1KO mice (Fig. 2.10B-C).  
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Figure	  2.10	  Intestinal	  fat	  absorption	  is	  inhibited	  in	  AEG-­‐1KO	  mouse.	  A.	  Serum	  total	  
cholesterol	  and	  triglyceride	  (TG)	  levels.	  (n=5/group).	  Measurement	  of	  newly	  synthesized	  
triglycerides	  (B)	  and	  palmitate	  (C).	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Figure	  2.11	  Triglycerides	  containing	  long-­‐chain	  fatty	  acids	  are	  increased	  in	  AEG-­‐1KO	  
mice	  Heat	  map	  of	  plasma	  lipid	  profile	  (n=4/group).	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 To assess rates of energy expenditure, an indirect calorimetry analysis 
was conducted measuring O2 consumption and CO2 production in WT and 
AEG1-KO mice, however these methods did not reveal any increased fat burning 
in AEG-1KO mice (Fig. 3.12A-B). In fact, AEG-1KO mice demonstrated a small 
but statistically significant decrease in energy expenditure compared to WT mice 
(Fig. 3.12B). No difference was observed in Uncoupling Protein 1 (UCP1) levels 
in white and brown adipose tissue of WT and AEG-1KO mice (data not shown).  
Next to be evaluated was intestinal lipid absorption. Cholesterol 
absorption was measured by oral gavage delivery of [14C]-cholesterol followed by 
measurement of radioactive fecal output. Fatty acid absorption was assessed by 
oral gavage delivery of [3H]-triolein followed by temporal measurement of plasma 
radioactivity. Both cholesterol and fatty acid absorption by the intestine were 
markedly inhibited in AEG-1KO as compared to WT mice (Fig. 2.13A-B). Taken 
together, this data suggested that the lean phenotype observed in AEG-1KO 
mice might be explained by reduced cholesterol and TG absorption from the 
intestine. 
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Figure	  2.12	  AEG-­‐1KO	  mice	  do	  not	  show	  increased	  fat	  burning.	  A.	  Indirect	  calorimetry	  
analysis	  measuring	  O2	  consumption	  and	  CO2	  production.	  B.	  Quantification	  as	  calculated	  
by	  quantifying	  the	  area	  under	  the	  curve.	  (n=6/group).	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Figure	  2.13	  Intestinal	  fat	  absorption	  is	  inhibited	  in	  AEG-­‐1KO	  mouse.	  A.	  Measurement	  
of	  cholesterol	  absorption	  from	  the	  intestine	  after	  oral	  gavage	  of	  [14C]-­‐cholesterol	  and	  
then	  measuring	  fecal	  radioactivity.	  B.	  Measurement	  of	  fatty	  acid	  absorption	  by	  oral	  
gavage	  of	  [3H]triolein	  and	  then	  temporally	  measuring	  plasma	  radioactivity.	  
A. 
B. 
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 To determine if intestinal cholesterol and TG absorption was indeed 
subjugated in AEG-1KO mice, the animals were maintained on a high fat and 
cholesterol containing diet (HFD). A cohort of WT and AEG-1KO mice were fed a 
HFD starting at 8 weeks of age. Over a period of 5 weeks, each WT mouse 
gained ~11 gm of body weight on average, while no weight gain was observed in 
AEG-1KO mice (Fig. 2.14B). The experiment was terminated early, since the 
AEG-1KO mice started developing steatorrhea with a tendency to actually lose 
body weight. Post mortem evaluation revealed evidence of steatosis in the liver 
of WT mice as a result of the HFD but this phenomenon was absent in AEG-1KO 
mice (Fig. 2.14A). The resistance of AEG-1KO mice to HFD induced weight gain 
indicated that intestinal fat and cholesterol absorption was indeed impaired. 
Moreover, the fact that mice actually lost weight suggests that high levels of fat 
and cholesterol were not only poorly tolerated but also inaccessible as an energy 
source in the AEG-1 KO mice. These findings indicate that feeding a HFD further 
aggravated the reduced cholesterol and TG absorption in AEG-1KO mice. 
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2.14	  AEG-­‐1KO	  Mice	  are	  resistant	  to	  high	  fat	  diet	  induced	  weight	  gain.	  A.	  H&E	  staining	  
of	  liver	  sections	  of	  mice	  fed	  HFD.	  B.	  Weekly	  body	  weight	  gain	  upon	  feeding	  high	  fat	  and	  
cholesterol	  diet	  (HFD).	  (n=8).	  For	  graphs,	  the	  data	  represent	  mean	  ±	  SEM.	  *:	  p<0.05.	  
A. 
B. 
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C. LXR and PPARα Activities are Augmented in the Intestine of AEG-1KO 
Mice 
 We next searched for the molecular mechanism conferring the phenotype 
observed in the AEG-1KO mice. As mentioned previously, our group has recently 
described a novel interaction between AEG-1 and Retinoid X Receptor (RXR), a 
transcription factor functioning as an obligate heterodimer partner of diverse 
nuclear receptors mediating the action of hormones, vitamins and lipids. LXR and 
PPARα are two heterodimeric binding partners of RXR that are essential to the 
absorption, transport, efflux and excretion of cholesterol and fatty acids (Fig. 
2.15, 2.16, 2.17). Based on the observed phenotype, we speculated that LXR 
and PPARα activity might be altered in AEG-1KO mice. To test this hypothesis, 
we first analyzed LXR and PPARα activity by means of luciferase reporter assays 
wherein primary WT and AEG-1KO hepatocytes were transfected with either 
LXRE or PPARE then treated with either T0901317 (5 uM) or CP775146 (2.5 
uM), synthetic ligands of LXR and PPARα respectively. Both basal and ligand-
dependent LXR and PPARα activities were significantly higher in AEG-1KO 
hepatocytes as compared to WT hepatocytes (Fig. 2.18A-B). 
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Figure	  2.15	  Intestinal	  cholesterol	  efflux.	  	  Intestinal	  cholesterol	  absorption	  (red	  arrows),	  
intestinal	  phytosterol	  handling	  (green	  arrows),	  and	  the	  role	  of	  enterocytes	  in	  fecal	  
excretion	  of	  cholesterol	  delivered	  from	  peripheral	  tissues	  by	  HDLs	  (i.e.	  alternative	  
reverse	  cholesterol	  transport,	  blue	  blue	  arrows).	  Cholesterol	  is	  absorbed	  from	  bile	  
micelles	  through	  the	  apical	  membrane	  NPC1L1	  protein.	  Most	  of	  it	  is	  subsequently	  
esterified	  by	  ACAT-­‐2,	  and	  cholesteryl	  esters	  are	  incorporated	  into	  chylomicrons	  (CHM),	  
which	  are	  exocytozed	  and	  enter	  the	  lymphatic	  capillaries.	  Some	  cholesterol	  is	  extruded	  
to	  the	  intestinal	  lumen	  through	  the	  apical	  ABCG5/ABCG8	  heterodimer	  and	  the	  minority	  
of	  cholesterol	  is	  extruded	  through	  the	  basolateral	  ABCA1	  to	  enter	  the	  HDL	  fraction,	  in	  
part	  formed	  locally	  in	  the	  intestine	  from	  locally	  generated	  apoAI.	  Alimentary	  
phytosterols	  are	  absorbed	  by	  NPC1L1,	  but	  are	  not	  esterified;	  most	  of	  them	  are	  rapidly	  
extruded	  to	  the	  gut	  lumen	  through	  the	  ABCG5/ABCG8	  complex	  and	  some	  phytosterols	  
are	  transferred	  to	  HDLs	  by	  basolateral	  ABCA1.	  In	  addition,	  the	  intestine	  may	  drive	  the	  
removal	  of	  peripheral	  tissue-­‐derived	  cholesterol	  from	  HDLs	  to	  the	  feces	  through	  the	  
concerted	  action	  of	  basolateral	  ABCA1	  and	  apical	  ABCG5/ABCG8.	  LXR	  agonists	  inhibit	  
NPC1L1	  and	  increase	  ABCA1,	  ABCG5,	  and	  ABCG8.	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Figure	  2.16	  PPARα	  Regulates	  Fatty	  Acid	  β-­‐Oxidation.	  Fatty	  acid	  β-­‐oxidation	  is	  the	  process	  by	  
which	  fatty	  acids	  are	  broken	  down	  to	  produce	  energy.	  PPARα	  regulates	  expression	  of	  a	  number	  
of	  genes	  involved	  in	  various	  steps	  of	  the	  β-­‐Oxidation	  pathway.	  Examples	  of	  proteins	  involved	  in	  
fatty	  acid	  β-­‐oxidation	  that	  are	  transcriptionally	  regulated	  by	  the	  PPARs	  are	  shown	  in	  blue.	  Fatty	  
acids	  primarily	  enter	  a	  cell	  via	  fatty	  acid	  protein	  transporters	  on	  the	  cell	  surface.	  Once	  inside,	  
FACS	  adds	  a	  CoA	  group	  to	  the	  fatty	  acid.	  CPT1	  then	  converts	  the	  long	  chain	  acyl-­‐CoA	  to	  long	  
chain	  acylcarnitine.	  The	  fatty	  acid	  moiety	  is	  transported	  by	  CAT	  across	  the	  inner	  mitochondrial	  
membrane.	  CPT2	  then	  converts	  the	  long	  chain	  acylcarnitine	  back	  to	  long	  chain	  acyl-­‐CoA.	  The	  
long	  chain	  acyl-­‐CoA	  can	  then	  enter	  the	  fatty	  acid	  β-­‐oxidation	  pathway,	  resulting	  in	  the	  
production	  of	  one	  acetyl-­‐CoA	  from	  each	  cycle	  of	  β-­‐oxidation.	  The	  acetyl-­‐CoA,	  the	  end	  product	  of	  
each	  round	  of	  β-­‐oxidation,	  then	  enters	  the	  TCA	  cycle,	  where	  it	  is	  further	  oxidized	  to	  CO2	  with	  
the	  concomitant	  generation	  of	  three	  moles	  of	  NADH,	  one	  mole	  of	  FADH2	  and	  one	  mole	  of	  ATP.	  
This	  acetyl-­‐CoA	  then	  enters	  the	  TCA	  cycle.	  The	  NADH	  and	  FADH2	  generated	  during	  the	  fat	  
oxidation	  and	  acetyl-­‐CoA	  oxidation	  in	  the	  TCA	  cycle	  then	  can	  enter	  the	  respiratory	  pathway	  for	  
the	  production	  of	  ATP	  via	  oxidative	  phosphorylation.	  The	  NADH	  and	  FADH2	  produced	  by	  both	  β-­‐
oxidation	  and	  the	  TCA	  cycle	  are	  used	  by	  the	  electron	  transport	  chain	  to	  produce	  ATP.
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Figure	  2.17	  β-­‐Oxidation	  Decreases	  Intestinal	  Absorption.	  Cholesterol	  is	  transported	  in	  the	  
plasma	  predominantly	  as	  cholesteryl	  esters	  associated	  with	  lipoproteins.	  Dietary	  cholesterol	  is	  
transported	  from	  the	  small	  intestine	  to	  the	  liver	  within	  chylomicrons.	  Cholesterol	  synthesized	  by	  
the	  liver,	  as	  well	  as	  any	  dietary	  cholesterol	  in	  the	  liver	  that	  exceeds	  hepatic	  needs,	  is	  transported	  
in	  the	  serum	  within	  LDLs.	  The	  liver	  synthesizes	  VLDLs	  and	  these	  are	  converted	  to	  LDLs	  through	  
the	  action	  of	  endothelial	  cell-­‐associated	  lipoprotein	  lipase.	  Cholesterol	  found	  in	  plasma	  
membranes	  can	  be	  extracted	  by	  HDLs	  and	  esterified	  by	  the	  HDL-­‐associated	  enzyme.	  The	  
cholesterol	  acquired	  from	  peripheral	  tissues	  by	  HDLs	  can	  then	  be	  transferred	  to	  VLDLs	  and	  LDLs	  
via	  the	  action	  of	  cholesteryl	  ester	  transfer	  protein	  (apo-­‐D)	  which	  is	  associated	  with	  HDLs.	  
Reverse	  cholesterol	  transport	  allows	  peripheral	  cholesterol	  to	  be	  returned	  to	  the	  liver	  in	  LDLs.	  
Ultimately,	  cholesterol	  is	  excreted	  in	  the	  bile	  as	  free	  cholesterol	  or	  as	  bile	  salts	  following	  
conversion	  to	  bile	  acids	  in	  the	  liver.	  Chylomicrons	  are	  assembled	  in	  the	  intestinal	  mucosa	  as	  a	  
means	  to	  transport	  dietary	  cholesterol	  and	  triglycerides	  to	  the	  rest	  of	  the	  body.	  Chylomicrons	  
are,	  therefore,	  the	  molecules	  formed	  to	  mobilize	  dietary	  (exogenous)	  lipids.	  The	  predominant	  
lipids	  of	  chylomicrons	  are	  triglycerides.	  The	  apolipoproteins	  that	  predominate	  before	  the	  
chylomicrons	  enter	  the	  circulation	  include	  apoB-­‐48	  and	  apoA-­‐I,	  apoA-­‐II	  and	  apoA-­‐IV.	  ApoB-­‐48	  
combines	  only	  with	  chylomicrons.	  Chylomicrons	  leave	  the	  intestine	  via	  the	  lymphatic	  system	  
and	  enter	  the	  circulation.	  In	  the	  bloodstream,	  chylomicrons	  acquire	  apoC-­‐II	  and	  apoE	  from	  
plasma	  HDLs.	  HDL	  begins	  as	  protein-­‐rich	  discoidal	  structures,	  composed	  primarily	  of	  apoA-­‐I,	  
produced	  by	  the	  liver	  and	  intestines.	  Within	  the	  vasculature	  apoA-­‐I	  interacts	  with	  the	  ATP-­‐
binding	  cassette	  transporter,	  ABCA1	  and	  extracts	  cholesterol	  from	  cells.	  Through	  the	  action	  of	  
LCAT	  the	  apoA-­‐I-­‐associated	  cholesterol	  is	  esterified	  forming	  cholesterol	  esters.	  This	  process	  
results	  in	  the	  generation	  of	  HDL3	  particles.	  As	  the	  HDL3	  particles	  continue	  through	  the	  circulation	  
they	  pick	  up	  more	  cholesterol	  and	  through	  the	  action	  of	  LCAT,	  generate	  more	  cholesterol	  esters.	  
As	  HDL	  migrates	  through	  the	  vasculature	  there	  is	  an	  interaction	  between	  them	  and	  IDL	  and	  LDL.	  
This	  interaction	  occurs	  through	  the	  action	  of	  CETP,	  which	  exchanges	  the	  cholesterol	  esters	  in	  the	  
HDL	  for	  triglycerides	  from	  LDL.	  This	  interaction	  results	  in	  the	  conversion	  of	  HDL3	  particles	  to	  
HDL2.	  HDL	  is	  then	  removed	  from	  the	  circulation	  by	  the	  liver	  through	  binding	  of	  the	  HDL	  to	  
hepatic	  scavanger	  receptor	  SR-­‐B1.	  Within	  the	  vasculature	  the	  generation	  of	  ROS	  results	  in	  
oxidation	  of	  lipid	  components	  of	  LDL	  generating	  oxidized	  LDL,	  which	  is	  taken	  up	  by	  macrophages	  
via	  the	  scavenger	  receptor,	  FAT/CD36.	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Figure	  2.18	  LXR	  and	  PPARα	  are	  activated	  in	  the	  intestine	  of	  AEG-­‐1KO	  mice.	  LXRE	  (A)	  
and	  PPARE	  (B)	  luciferase	  activity	  was	  determined	  in	  WT	  and	  AEG-­‐1KO	  hepatocytes	  upon	  
treatment	  with	  LXR	  ligand,	  T0901317	  (T0)	  (5	  μM),	  and	  PPARα	  ligand,	  CP775146	  (CP)(2.5	  
μM),	  respectively. R.L.U.:	  relative	  luciferase	  unit. 
A. B. 
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 The next step was to evaluate the functional relevance of this mechanism 
in vivo. To do so WT and AEG-1KO mice were treated with T0901317. After 24 h 
the animals were sacrificed and livers were analyzed for recruitment of LXR, 
acetylated histone H3 (AHH3) and co-activator SRC-1 on the promoter region of 
LXR target gene Abca1 by chromatin immunoprecipitation (ChIP) (Fig. 2.19). A 
significant increase in recruitment of LXR, was observed in AEG-1KO livers 
versus WT livers. AHH3 and SRC-1activity were also elevated in AEG-1KO mice 
as compared to the WT indicating an increase in co activator activity and 
recruitment respectively. This in vivo analysis confirmed and validated our 
previous in vitro observations. 
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Figure	  2.19	  LXR	  is	  activated	  in	  AEG-­‐1KO	  mice.	  ChIP	  assays	  were	  performed	  using	  anti-­‐
LXRα/β,	  anti-­‐Acetyl	  Histone	  H3	  (AHH3)	  and	  anti-­‐SRC-­‐1	  antibodies	  using	  T0901317-­‐
treated	  WT	  and	  AEG-­‐1KO	  livers	  and	  PCR	  primers	  amplifying	  promoter	  regions	  of	  Abca1	  
gene.	  Normal	  rabbit	  IgG	  was	  used	  as	  control	  and	  the	  data	  was	  normalized	  by	  results	  
obtained	  using	  normal	  IgG.	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 Next we analyzed the expression of a number of LXR target genes in the 
small intestine of WT and AEG-1KO mice fed either regular chow or HFD. The 
basal expression level of Abca1 was markedly higher in chow fed-AEG-1KO 
mice compared to WT mice (Fig. 2.20A). With regular chow, the heterodimeric 
efflux pump Abcg5 and Abcg8 showed small but significant increase in AEG-1KO 
versus WT mice. Upon HFD treatment, the expression of all three genes was 
significantly induced in both WT and AEG-1KO mice. However, the magnitude of 
induction of these genes was significantly more robust in AEG-1KO mice 
compared to WT mice, particularly in the case of Abca1 (Fig. 2.20A). Conversely, 
the basal expression level of the cholesterol transporter Npc1l1 was significantly 
lower in AEG-1KO mice versus WT mice and upon HFD treatment levels were 
further depressed (Fig. 2.20B). It can be reasoned that the increased levels of 
the cholesterol efflux pumps and decrease in the cholesterol transporter (Npc1l1) 
explains the inhibition of intestinal cholesterol absorption in AEG-1KO mice. Even 
more compelling is the fact that these effects were further intensified when the 
animals were challenged with HFD, which provides ligands to LXR, functionally 
activating LXR and augmenting its activity. 
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Figure	  2.20	  LXR	  is	  activated	  in	  the	  intestine	  of	  AEG-­‐1KO	  mice.	  Expression	  of	  the	  
indicated	  genes	  by	  Taqman	  Q-­‐RT-­‐PCR	  in	  small	  intestine	  of	  chow-­‐	  and	  HFD-­‐fed	  mice.	  The	  
data	  represent	  mean	  ±	  SEM.	  *:	  p<0.05	  versus	  corresponding	  data	  point	  in	  WT	  mice;	  #:	  
p<0.05	  chow	  versus	  HFD	  in	  WT	  mice;	  ^:	  p<0.05	  chow	  versus	  HFD	  in	  AEG-­‐1KO	  mice. 
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 A number of PPARα target genes that are known regulators of β-oxidation 
of fatty acids in the small intestine and liver. We analyzed the expression levels 
of several of the key genes involved in this process, however no significant 
difference was observed in the enterocyte expression levels of fatty acid 
transporters, FABPpm/Got2, FAT/Cd36 and FATP4/Slc27a4 in WT and AEG-
1KO mice (Fig. 2.21A) with regular chow or HFD. This indicated that fatty acid 
transport from the lumen to the enterocytes was not dysregulated in the KO 
animals and that enhanced β-oxidation may be responsible for the observed 
decreased absorption to the plasma. Fatty acid degradation in most organisms 
occurs primarily via the β-oxidation cycle. The major degradative pathway for 
fatty acid esters is β-oxidation. In mammals, β-oxidation occurs in both 
mitochondria and peroxisomes thus we analyzed components of both organelles. 
For the mitochondrial β-oxidation pathway, Cpt1a, the rate-limiting enzyme in the 
carnitine-dependent transport of fatty acids across the mitochondrial membrane 
was analyzed as well as Acadl and Acadm, which catalyze the initial steps of 
fatty acid β-oxidation [73]. For peroxisomal β-oxidation, we analyzed Acox1, the 
first enzyme in this pathway [73]. In standard chow fed mice, Cpt1a and Acadl 
expression levels were significantly higher in the small intestine (Fig. 2.21B), and 
Cpt1a, Acadl and Acadm levels were significantly higher in the liver of AEG-1KO 
mice versus WT mice (Fig. 2.21B). There were no significant differences in the 
Acox1 levels between AEG-1KO and WT mice in either organ. Interestingly 
however, a significant induction of all four genes was observed in both the small 
intestine and liver of WT mice following exposure to a HFD. In the small intestine 
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of AEG-1KO mice, HFD treatment resulted in a significant induction of all four 
genes, which was substantially more pronounced than the induction seen in WT 
mice (Fig. 2.21B-C). However, HFD treatment did not result in further induction of 
these genes in the liver of AEG-1KO mice (Fig. 2.21C).  
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Figure	  2.21	  Expression	  of	  fatty	  acid	  transporters	  and	  PPARα	  target	  genes.	  	  Expression	  
of	  the	  indicated	  genes	  by	  Taqman	  Q-­‐RT-­‐PCR	  in	  chow-­‐	  and	  HFD-­‐fed	  small	  intestine	  (A	  &	  
B)	  and	  chow-­‐	  and	  HFD-­‐fed	  liver	  (C).	  The	  data	  represent	  mean	  ±	  SEM.	  *:	  p<0.05	  versus	  
corresponding	  data	  point	  in	  WT	  mice;	  #:	  p<0.05	  chow	  versus	  HFD	  in	  WT	  mice;	  ^:	  p<0.05	  
chow	  versus	  HFD	  in	  AEG-­‐1KO	  mice.	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 We also directly assessed the levels of Ppara in these animals and found 
that the basal Ppara level was also significantly higher in the small intestine (Fig. 
2.22A) and liver (Fig. 2.22B) of AEG-1KO mice as compared to WT mice. HFD 
treatment resulted in induction of Ppara in both WT and AEG-1KO liver and small 
intestine. However, here again we saw that the magnitude of induction was much 
more pronounced in the small intestine of AEG-1KO mice than in the WT (Fig. 
2.22A-B). Intriguingly we also observed that the HFD-mediated induction of 
Ppara was more robust in the small intestine than in the liver of the AEG-1KO 
mice, (Fig. 2.22A-B). No significant differences were observed in the levels of 
Pparg or of Ppargc1, the co-activator for PPAR (Fig. 2.22A-B).  
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Figure	  2.22	  PPAR	  Expression.	  Expression	  of	  the	  indicated	  genes	  by	  Taqman	  Q-­‐RT-­‐PCR	  in	  
chow-­‐	  and	  HFD-­‐fed	  small	  intestine	  (S.I.)	  (A)	  and	  chow-­‐	  and	  HFD-­‐fed	  liver	  (B).	  The	  data	  
represent	  mean	  ±	  SEM.	  *:	  p<0.05	  versus	  corresponding	  data	  point	  in	  WT	  mice;	  #:	  p<0.05	  
chow	  versus	  HFD	  in	  WT	  mice;	  ^:	  p<0.05	  chow	  versus	  HFD	  in	  AEG-­‐1KO	  mice.	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 Collectively these findings suggest that under basal conditions higher 
levels of PPARα and its target genes in the small intestine of AEG-1KO mice 
confer increased fatty acid β-oxidation in the enterocytes, resulting in decreased 
fatty acid absorption. This effect is heightened upon HFD treatment that provides 
ligands to PPARα, thus augmenting levels of both Ppara and its target genes. 
The lack of absorption of fatty acids from the intestines upon HFD treatment 
results in decreased delivery of PPARα ligands to the liver, so that there was no 
further induction by HFD compared to chow diet. The mitochondrial FA β-
oxidation pathway is a major contributor to cellular energy production and 
homeostasis. To directly evaluate and quantify the rate of β-oxidation in vivo, 
products of fatty acid β-oxidation were measured in fresh liver and small intestine 
homogenates using 14C-palmitate. Acetyl-CoA, generated by β-oxidation, enters 
TCA cycle to generate CO2. 14C-palmitate that does not get oxidized forms acid-
soluble metabolites (ASM). Fatty acid β-oxidation was significantly increased in 
the liver and small intestine of AEG-1KO mouse versus WT (Fig. 2.23).  
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Figure	  2.23	  Fatty	  acid	  β-­‐oxidation	  is	  increased	  in	  AEG-­‐1KO	  mice.	  A.	  Fresh	  liver	  and	  B.	  
small	  intestine	  homogenates	  were	  used	  with	  14C-­‐palmitate	  as	  substrate.	  The	  data	  
represent	  mean	  ±	  SEM	  of	  3	  independent	  experiments.	  *:	  p<0.01.	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IV. Discussion 
 Knockout of AEG-1 confers a lean phenotype marked by increased overall 
longevity in mice. In this study we systematically assessed many of the major 
known contributors to metabolic homeostasis.  We were unable to identify any 
impairment in triglyceride synthesis in AEG-1KO mice. Similarly, calorimetric 
analysis did not provide evidence of increased energy expenditure in AEG-1KO 
mice nor did differences exist in glucose tolerance indicating that the lack of 
excess body fat and overall lean phenotype observed in AEG-1KO mice was not 
owed to aberrant fat production, increased energy expenditure or differential 
glucose management. A significant decrease in serum total triglyceride (TG) and 
cholesterol levels was observed in AEG-1KO mice as compared to WT. Our 
studies revealed a dramatic reduction in both cholesterol and fatty acid 
absorption in the intestine of AEG-1KO mice. The phenotypes observed in AEG-
1KO mice may be explained by hyperactivity of RXR heterodimer partners LXR 
and PPAR-α. In enterocytes, activation of LXR inhibits cholesterol absorption and 
activation of PPAR-α promotes β-oxidation of fatty acids resulting in inhibition of 
fatty acid absorption.  When fed a regular chow diet basal intestinal expression of 
LXR target genes, Abca1, Abcg5 and Abcg8 were elevated and Npc1l1 levels 
were reduced in the intestines of AEG-1KO mice as compared to WT. This 
difference was dramatically amplified upon feeding a HFD which provide ligands. 
Similar findings were also observed for PPAR-α target genes involved in fatty 
acid β-oxidation such as Cpt1a, Acox1, Fabp1, Acadl and Acadm. Cholesterol 
and fatty acid absorption from the intestine is a complicated process involving 
specific transporters and efflux pumps, the expression of which is regulated by 
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nuclear receptors, such as LXR and PPAR-α [62, 74]. In addition, metabolism of 
cholesterol and fatty acids in enterocytes determine their absorption into the 
lymph and blood and availability to other organs. Unesterified free cholesterol is 
taken up into the enterocytes by the cholesterol transporter NPC1L1 which can 
have three fates [62]. Free cholesterol can be transported to the ER where it is 
esterified by Acyl-CoA:cholesterol acyltransferase 2 (ACAT2) enzyme and then 
conjugated with ApoB48 to form chylomicrons which enter into the lymphatic 
system. Unesterified free cholesterol can be transported back to the intestinal 
lumen by apically located cholesterol pump ABCG5/ABCG8 heterodimer. Free 
cholesterol can also be transported into the circulation as a constituent of HDL 
via ABCA1 located on the basolateral membrane of the enterocytes. When 
cellular oxysterols accumulate as a result of increasing concentrations of 
cholesterol, LXR activation, by cholesterol metabolites such as oxysterols [60], 
causes a net loss of cholesterol through downregulation of NPC1L1 and 
reduction of ACAT2 enzyme activity as well as induction of ABCG5/ABCG8 and 
ABCA1 [75-77].  
 Important intestinal fatty acid transporters include: (1) Fatty acid binding 
protein, plasma membrane (FABPpm/Got2), located peripherally on the plasma 
membrane; (2) Fatty acid translocase (FAT/CD36), an integral membrane 
glycoprotein; and (3) Fatty acid transport protein subtype 4 (FATP4/Slc27a4), an 
integral membrane protein [78]. In the intestinal lumen triglycerides are broken 
down into free fatty acids by lipases. Once fatty acids enter into the enterocytes 
cytoplasmic fatty acid binding protein (FABPc) may transport them to the 
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mitochondria for β-oxidation [79]. The majority of fatty acids are re-esterified into 
TG and excreted into chylomicrons. In the enterocytes, PPAR-α promotes β-
oxidation of fatty acids thereby decreasing fatty acid absorption in the circulation 
[64, 74]. This work provides a conceptual framework for understanding the role of 
AEG-1 in normal physiology. Up until now AEG-1 has been known only for its 
role in tumorigenesis. Here for the first time we show that the lack of AEG-1 in 
mice augments LXR and PPARα activity, thereby preventing fat absorption from 
the intestine. Taken together these findings provide evidence that AEG-1 plays 
an essential role in maintaining homeostasis in lipid metabolism. These findings 
have important implications for a number of different pathological conditions, 
including obesity and non-alcoholic fatty liver disease (NAFLD), where AEG-1 
overexpression may facilitate increased fat availability, and may contribute to fat 
accumulation and ultimately cirrhosis of the liver and obesity-associated cancers. 
These findings highlight AEG-1 as a new potential target to therapeutic 
intervention of obesity-associated illnesses.  
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Chapter Three-The role of Astrocyte Elevated Gene-1 in the Onset and 
Progression of Hepatocellular Carcinoma 
 
I. Summary 
AEG-1 plays a key role in carcinogenesis. Activation of NF-κB in liver 
macrophages is pivotal for N-nitrosodiethylamine (DEN)-induced HCC initiation. 
We previously documented that AEG-1 is an essential component of NF-κB 
activation. In the present studies we interrogated the role of AEG-1 in 
hepatocarcinogenesis using an AEG-1 knockout mouse (AEG-1KO) model. 
AEG-1KO mice showed profound resistance to DEN- as well as DEN- and 
phenobarbital (PB)-induced HCC and lung metastasis. No differential signaling in 
response to growth factors was observed in AEG-1KO mouse hepatocytes 
compared to those of the Wild Type (WT) nor did we identify any differences in 
activation of the Akt, ERK or β-catenin pathways which are known to be activated 
by AEG-1 overexpression. Profound inhibition of NF-κB activation was observed 
in AEG-1KO hepatocytes and macrophages as compared to the WT. A marked 
inhibition in IL-6 production and in STAT-3 activation, key mediators of HCC 
development, was also observed in DEN-treated AEG-1KO mice. Conditioned 
media from hepatocytes failed to induce IL-6 expression in macrophages in AEG-
1KO, but not in WT. Inhibition of myeloid cell migrations and inhibition of 
activation of granulocytes were the key functional consequences gleaned by 
analyzing global gene expression changes in AEG-1KO mice versus WT. These 
findings suggest that AEG-1 is essential for NF-κB activation and inhibition of this 
activation in macrophages and hepatocytes might confer protection to AEG-1KO 
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mice from hepatocarcinogenesis. Our studies, for the first time, unravel a unique 
role of AEG-1 in tumor microenvironment that is critical for initial development of 
HCC upon DEN-induced mutagenesis. 
 
II. Hepatocellular Carcinoma 
 Hepatocellular carcinoma (HCC) is defined as malignant transformation of 
hepatocytes, the primary and most abundant cell type in the liver. Chronic liver 
diseases contribute to most cases of HCC, most frequently as a consequence of 
viral hepatitis B (HBV) infection [80]. HCC has a high prevalence in Asian 
countries because of endemic HBV infection. However, the incidence of HCC 
has been rising in Western countries over the past 20 years due to increasing 
rates of viral hepatitis C (HCV) infection and chronic alcoholism [81]. In addition 
to HBV and HCV infection, heavy alcohol intake, toxic exposures, non alcoholic 
fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), obesity and 
diabetes through the development of NAFLD and NASH are also well 
documented risk factors leading to hepatocarcinogenesis [80]. It is important to 
note that the majority of documented risk factors result in cirrhotic liver damage 
as HCC onset is almost exclusively seen in patients suffering from long term liver 
inflammation or cirrhosis. HCC in the United States is characterized by significant 
variations in incidence by age, gender and race [81]. HCC is rare before age 40, 
rises in incidence progressively thereafter peaking between the ages of 70–75 
with a mean diagnosis age of approximately 65 years [80]. The racial distribution 
of patients is 48% Caucasian, 15% Hispanic, 13% African American, and 24% 
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other (predominantly Asian) [80]. At all ages and in all racial/ethnic groups in the 
US, HCC is 3–4 times more common in men than in women with an astounding 
74% of cases occurring in men [80]. Higher levels of testosterone, higher body 
mass index, and higher rates of liver disease are proposed explanations for this 
significantly increased risk in men [81]. By and large HCC, particularly in the 
early stages is asymptomatic, going unnoticed until the disease has reached 
intermediate or advanced stages when conventional therapies are less effective 
[82]. Treatment options for HCC depend upon the stages, grades and localization 
of the disease [83]. Standard treatment options for patients afflicted with localized 
forms of the disease include surgical resection, liver transplantation, 
radiofrequency ablation, and chemoembolization [84] [85]. Unfortunately, the 
majority of HCC cases involve advanced tumors with underlying cirrhotic 
changes wherein surgical resection or transplantation are not viable options [56]. 
If tumors are not removed, patients generally survive between 3-6 months. Only 
10 - 20% of HCC’s can be removed completely by surgical [86]. Even after 
surgical resection, HCC recurrence rate is extremely high culminating into an 
overall high mortality rate for this disease. One of the primary reasons for such 
high mortality rates amongst HCC patients is the lack of effective treatment 
options, especially for those in the more advanced stages of the disease. 
Although surgery and percutaneous ablation has been shown to achieve long-
term control in some early HCC cases, it reappears in close to 50% of such 
cases after approximately 3 years [86]. Due to the asymptomatic nature of early 
HCC, the lack of awareness and poorly defined screening strategies, close to 
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80% of patients present with advanced or unresectable disease [86]. These 
patients generally have a very poor prognosis thus treatment options are mainly 
palliative [86]. Studies have explored the use of transarterial chemoembolization 
(TACE) and systemic therapy with doxorubicin alone or a combination of 
cisplatin, IFN, doxorubicin, and 5-fluorouracil (5-FU) as options for patients 
ineligible for liver resection, ablation or transplantation [87] [88]. However, clinical 
trials incorporating these therapies yielded disappointing results as patients 
showed only moderate improvements in survival time [87] [88] This lack of 
response to such treatments suggests that chemoresistance may be an inherent 
trait of HCC and there are currently no systemic therapies available for the 
metastatic disease [89]. Cancer has been described as a DNA disease caused 
by the accumulation of alterations in genes in a process of confounding genetic 
and epigenetic alterations [90]. It is clear that this theory holds true for 
hepatocarcinogenesis. In most cases HCC is a progression from chronic 
hepatitis, to cirrhosis, to dysplastic nodules, to malignant tumors. However; clear 
and specific sequences of genetic events have yet to be elucidated in the 
progression of HCC. The fact that no consistent genomic abnormalities have 
been identified in the disease may be largely due to the numerous etiologies 
linked to HCC. It is clear that identification of integral molecules involved in the 
genetic and subsequent pathway dysregulation is a critical step in the 
development of effective therapeutics for the treatment of HCCNF-κB is a key 
transcriptional regulator of the inflammatory response and plays an essential role 
in regulating inflammatory signaling in the liver [91, 92]. NF-κB activation is a 
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frequent and early event in human HCC of viral and non-viral etiologies and has 
been attributed to the acquisition of transformed phenotype during 
hepatocarcinogenesis [93-97]. Both HBV X protein (HBX) and HCV core protein 
have been shown to activate NF-κB by multiple mechanisms [95, 98, 99]. Many 
patients with advanced liver disease present with increased levels of LPS, 
resulting in activation of NF-κB in the liver [100]. Fatty acids may also activate 
NF-κB in NAFLD patients [101]. 
 The role of NF-κB in HCC development and progression has been 
interrogated in several mouse models. Mdr2-/- mice develop spontaneous 
cholestatic hepatitis and HCC [91]. Overexpression of a non-degradable mutant I 
IκBα  that blocks NF-κB activation significantly inhibited HCC progression in this 
model [91]. Knockout of IKKβ  in hepatocytes abrogated HCC development in a 
transgenic mouse model overexpressing lymphotoxin α and/or β [102]. These 
findings indicate that NF-κB activation in hepatocytes is necessary in 
inflammation-induced HCC. In contrast, hepatocyte-specific knockout 
IKKβ promoted HCC development in N-nitrosodiethylamine (DEN)-initiation 
model and hepatocyte-specific knockout of IKKγ (NEMO) resulted in 
spontaneous development of HCC [103, 104]. ROS-induced JNK and STAT3 
activation has been suggested to promote HCC in IKKβ knockout model and 
IKKβ has been suggested to inhibit both hepatic injury and proliferation [105]. 
However, deletion of IKKβ in macrophages significantly abrogated DEN-induced 
HCC [103]. Additionally genetic deletion of IL-6 or inhibition of inflammatory 
cytokines, such as TNF-α, provided a significant reduction in tumor load [106]. 
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Injury to hepatocytes, such as those caused by DEN, leads to release of IL-
1α that activates NF-κB in liver macrophages (Kupffer cells) with subsequent 
release of cytokines, such as IL-6 [106-108]. IL-6 promotes proliferation and 
survival of hepatocytes by activating STAT-3 signaling [106]. Thus, NF-κB 
activation in the tumor microenvironment plays a fundamental role in 
hepatocarcinogenesis. 
 
III. The Role of AEG-1 in Hepatocarcinogenesis 
 AEG-1, also known as Metadherin (MTDH) and LYRIC, is an oncogene 
that is overexpressed in all cancers [53]. AEG-1 overexpression is detected with 
the progression of cancer, especially in the aggressive metastatic stage, and 
negatively correlates with poor survival and overall adverse prognosis [53]. In 
vitro studies and investigations using nude mice xenograft and metastatic models 
with diverse cancer cell lines documented that AEG-1 overexpression induces an 
aggressive, angiogenic and metastatic phenotype whereas knockdown of AEG-1 
inhibits proliferation and invasion and markedly abrogates tumor growth and 
metastasis [2, 9, 51, 52].  Conversely, siRNA inhibition of AEG-1 effectively 
inhibited the growth of cancer cells in nude mice xenograft and metastatic 
models further implicating AEG-1 as an integral component of cancer 
pathogenesis [51]. AEG-1 plays an important role in regulating 
hepatocarcinogenesis. Our group previously documented AEG-1 overexpression 
at both mRNA and protein levels in a high percentage (>90%) of HCC patients 
and a significant percentage of patients harbored genomic amplification of the 
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AEG-1 locus in chromosome 8q22 [51]. Immunohistochemical analysis of 109 
human HCC patient samples detected variable levels of AEG-1 that directly 
correlated with the stages of the disease with 94 percent efficiency, based on the 
Barcelona Clinic Liver Cancer (BCLC) staging system (Figure 2A-H) [51].  These 
data were further substantiated by gene expression, microarray analysis of 132 
human samples. The analysis compared normal liver, cirrhotic liver, low-grade 
dysplastic nodules, high-grade dysplastic nodules and HCV-related HCC tissue 
samples (Figure 3). AEG-1 expression is significantly increased in HCC as 
compared to the normal liver and cirrhotic tissue samples [51]. Microarray 
analysis has identified that overexpression of AEG-1 in human HCC cells results 
in profound modulation of expression in genes regulating chemoresistance, 
senescence, metastasis, angiogenesis and invasion [89]. These same cell lines 
also exhibit an AEG-1 mediated upregulation of several cell proliferation and 
prosurvival signaling cascades [109] [110] [111] [112]. These findings suggest 
that a direct relationship exists between the level of AEG-1 expression and the 
stage of the disease. AEG-1 is transcriptionally regulated by c-Myc [15], an 
oncogene frequently upregulated in HCC [113]. The tumor suppressor miRNA 
miR-375, which is downregulated in HCC patients, targets AEG-1 [21]. Thus 
AEG-1 overexpression occurs by multiple mechanisms in HCC patients. HCC 
with more microvascular invasion or pathologic satellites, poorer differentiation, 
and TNM stages II to III are prone to exhibit higher AEG-1 expression [114]. HCC 
patients with high AEG-1 expression documented higher recurrence and poor 
overall survival [114, 115]. Overexpression of AEG-1 in a poorly aggressive HCC 
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cell line HepG3, which expresses low level of AEG-1, significantly increases in 
vitro proliferation, invasion and anchorage-independent growth and in vivo 
tumorigenesis, angiogenesis and metastasis in nude mice [51]. Conversely, 
knockdown of AEG-1 in highly aggressive QGY-7703 cells, expressing high 
levels of AEG-1, significantly abrogates in vivo tumorigenesis [51, 55]. We have 
shown that transgenic mice with hepatocyte-specific overexpression of AEG-1 
(Alb/AEG-1) do not show spontaneous HCC but develop highly aggressive 
angiogenic HCC with significantly accelerated kinetics upon treatment with DEN 
when compared to their WT counterparts [54]. AEG-1 overexpression profoundly 
modulates expression of genes associated with proliferation, invasion, 
chemoresistance, angiogenesis and metastasis in both human HCC cell lines 
and Alb/AEG-1 hepatocytes [51, 54]. 
 Multiple pro-survival signaling pathways, such as NF-κB, PI3K/Akt, Wnt/β-
catenin and MEK/ERK, become activated upon overexpression of AEG-1 in 
human cancer cells and Alb/AEG-1 hepatocytes [51, 54]. Pharmacological and 
genetic inhibition studies have elucidated the importance of all these signaling 
pathways in mediating AEG-1-induced oncogenesis [51]. However, apart from 
NF-κB, the molecular mechanism by which AEG-1 activates these signaling 
pathways is not known. More importantly, whether AEG-1 is required for 
activation of these pathways under physiological conditions has not been 
investigated. We have documented that AEG-1 directly interacts with the p65 
subunit of NF-κB and CBP thereby functioning as a bridging factor between NF-
κB and basal transcriptional machinery promoting NF-κB-induced transcription 
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[11, 12]. A recent study has documented that AEG-1, anchored on the ER 
membrane, associates with upstream ubiquitinated activators of NF-κB, such as 
RIP1 and TRAF2, facilitating their accumulation and subsequent NF-κB 
activation [116]. 
 In this chapter, the response of AEG-1 knock-out (AEG-1KO) mouse to 
DEN-induced HCC development and progression is analyzed. The experiments 
described here unravel a fundamental role of AEG-1 in regulating NF-κB 
activation, especially in the tumor microenvironment, thereby rendering AEG-
1KO mice to be significantly resistant to initiation and progression of HCC.   
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IV. Materials and methods 
Mouse model: 
 AEG-1KO mouse was generated in C57BL/6:129/Sv background and the 
procedure is described in detail in the supplement. We have backcrossed the line 
to C57BL/6 for 10 generations and obtained similar results for both the WT and 
AEG-1KO mice on the C57BL/6 background as on the C57BL/6:129/Sv 
background. AEG-1KO mice were viable and fertile, although litter sizes were 
very small (1-2 pups per litter). Further, even litters generated by crossing AEG-
1+/- breeding pairs were very small (2-3 pups per litter), which precluded 
generating large numbers of WT and AEG-1KO mice as littermates. Therefore, 
the majority of the experiments were carried out with age-matched mice 
generated by breeding WT and AEG-1KO mice separately. However, it should be 
noted that the same phenotypes were observed in AEG-1KO mice generated 
from AEG-1+/- X AEG-1+/- mating as from AEG-1KO X AEG-1KO mating. Thus 
our findings are not restricted to strains or littermates. All animal studies were 
approved by the Institutional Animal Care and Use Committee at Virginia 
Commonwealth University, and were conducted in accordance with the Animal 
Welfare Act, the PHS Policy on Humane Care and Use of Laboratory Animals, 
and the U.S. Government Principles for the Utilization and Care of Vertebrate 
Animals Used in Testing, Research, and Training. 
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Cell culture:  
Primary mouse hepatocytes were isolated as described [54] and were cultured in 
Williams E medium containing NaHCO3, L-glutamine, insulin (1.5 uM) and 
dexamethasone (0.1 uM) at 37°C and in 5% CO2. For isolating primary perinoeal 
macrophages, mice were injected i.p. with 4% thioglycollate and 4 days later 
macrophages were harvested in PBS via i.p. injection. Macrophages were 
cultured in Dulbecco’s Modified Eagle’s Medium with 10% fetal calf serum at 
37°C and in 5% CO2. 
 
Transient transfection and luciferase assay: 
 For transfections, 1X105 hepatocytes were plated in 24-well collagen coated 
plates and the next day transfected using Promofectin-Hepatocyte transfection 
reagent in 9:1 ratio of NF-κB luciferase reporter plasmid and renilla luciferase 
reporter plasmid. After 48 hours, cells were treated with LPS (200 ng/ml) for 24 h. 
Luciferase assays were measured using Dual Luciferase Reporter Assay kit 
(Promega) following manufacturer’s protocol and firefly luciferase activity was 
normalized by renilla luciferase activity. Each experiment was performed in 
triplicates and three times to calculate means and standard errors. 
 
Total RNA extraction, cDNA preparation and Real time PCR: 
 Total RNA was extracted from hepatocytes, macrophages or mouse tissues 
using the QIAGEN miRNAeasy Mini Kit (QIAGEN, Valencia, CA). cDNA 
preparation was done using ABI cDNA synthesis kit (Applied Biosystems, Foster 
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City, CA). Real-time polymerase chain reaction (RT-PCR) was performed using 
an ABI ViiA7 fast real-time PCR system and Taqman gene expression assays 
according to the manufacturer’s protocol (Applied Biosystems, Foster City, CA). 
 
RNA sequencing (RNA-Seq):  
Total RNA, extracted using Qiagen miRNAeasy mini kit (Qiagen, Valencia, CA) 
from livers of 3 adult mice per group, was employed for RNA sequencing. RNA-
Seq library was prepared using Illumina TruSeq RNA sample preparation kit and 
sequenced on Illumina HiSeq2000 platform. RNA-Seq libraries were pooled 
together to aim about 25-40M read passed filtered reads per sample. All 
sequencing reads were aligned with their reference genome (UCSC mouse 
genome build mm9) using TopHat2 and the Bam files from alignment were 
processed using HTSeq-count to obtain the counts per gene in all samples. The 
counts were read into R software using DESeq package and plot distributions 
were analyzed using Reads Per Kilobase Million (RPKM) values. Data were 
filtered based on low count or low RPKM value (<40 percentile). Pairwise tests 
were performed between each group using the functions in DESeq. Genes 
showing log2 fold-change of >1.5 or <-1.5, FDR of <0.1 and p-value of <0.01 
were selected. 
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Statistical analysis:  
Data were represented as the mean ± Standard Error of Mean (S.E.M) and 
analyzed for statistical significance using one-way analysis of variance (ANOVA) 
followed by Newman-Keuls test as a post hoc test. 
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V. Results 
A. AEG-1KO Mice are Resistant to Age Associated Spontaneous Tumor 
Formation 
 No histological difference was observed in the internal organs of young 
adult AEG-1KO (8-12 weeks old) mice when compared to WT littermates or age-
matched WT mice (Fig. 3.1A). Analysis of bone marrow, peripheral blood cells 
and spleen cell composition at this age also showed no difference (Table 3.1, 
Table 3.2 and Fig. 3.2). However, when aged (16 months), spontaneous age 
associated-tumorigenesis was observed in multiple organs a number of WT 
mice, however this phenomenon was completely absent in the AEG-1KO mice (n 
= 20) (Fig. 3.1A and 3.1B). Age-associated lymphoma and adenocarcinoma were 
observed in the liver, adenocarcinoma and carcinoid tumors were observed in 
the lungs and myxoma was observed in the heart of the aged WT mice. 
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Figure	  3.1	  AEG-­‐1KO	  mice	  are	  resistant	  to	  age-­‐associated	  spontaneous	  tumorigenesis.	  
A.	  H	  &	  E	  staining	  of	  the	  indicated	  tissue	  sections	  of	  aged	  (16	  m)	  AEG-­‐1KO	  mouse	  
demonstrating	  maintenance	  of	  normal	  histology	  and	  architecture.	  B.	  H	  &	  E	  staining	  of	  
sections	  of	  liver,	  lung	  and	  heart	  of	  aged	  (16	  m)	  WT	  mouse	  showing	  tumors.	  C.	  
Immunohistochemical	  staining	  for	  AEG-­‐1	  in	  liver	  lymphoma	  of	  WT	  mouse.	  D.	  F4/80	  
staining	  for	  macrophages	  in	  liver	  sections	  of	  aged	  (16	  m)	  WT	  and	  AEG-­‐1KO	  mouse. 
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Table	  3.1.	  Differential	  count	  of	  bone	  marrow	  cells	  of	  adult	  WT	  and	  AEG-­‐1KO	  mice.	  
Bone	  marrow	  was	  collected	  from	  8	  weeks	  old	  WT	  and	  AEG-­‐1KO	  mice.	  Bone	  marrow	  
smear	  was	  made	  and	  stained.	  Two	  hundred	  cells	  were	  counted	  to	  obtain	  differential	  
count.	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Table	  3.2.	  Complete	  blood	  count	  of	  peripheral	  blood	  in	  WT	  and	  AEG-­‐1KO	  mice.	  
Peripheral	  blood	  was	  collected	  from	  WT	  and	  AEG-­‐1KO	  mice	  and	  analyzed	  for	  complete	  
blood	  count.	  WBC:	  white	  blood	  cells;	  RBC:	  red	  blood	  cells;	  HCT:	  hematocrit;	  MCV:	  mean	  
corpuscular	  volume.	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Figure	  3.2.	  Analysis	  of	  spleen	  cells	  of	  adult	  WT	  and	  AEG-­‐1KO	  mice.	  Spleen	  leukocyte	  as	  
analyzed	  by	  flow	  cytometry	  show	  no	  significant	  differences	  between	  wild-­‐type	  and	  AEG-­‐
1KO	  mice	  in:	  the	  frequency	  of	  NK1.1+CD3-­‐	  natural	  killer	  cell,	  CD3+	  T	  cell	  or	  their	  subsets	  
(i.e.,	  CD4+CD3+,	  CD8+CD3+),	  B220+	  B	  cell,	  CD11b+	  myeloid	  cell	  or	  their	  subsets,	  
including	  macrophage	  (CD11b+F4/80+),	  dendritic	  cell	  (CD11b+CD11c+),	  monocyte	  
(CD11b+Ly6ChighLy6G-­‐),	  or	  neutrophils	  (CD11b+Ly6ClowLy6G+).	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Interestingly the spontaneous tumors developing in the livers of WT mice 
stained strongly for AEG-1, especially those cells invading into the surrounding 
liver parenchyma, further confirming the essential role of AEG-1 in regulating 
tumor invasion (Fig. 3.1C). Marked infiltration of macrophages, evidenced by 
staining for macrophage marker F4/80, was observed in the aged (16 m old) WT 
liver but not in AEG-KO liver (Fig. 3.1D). No difference in infiltration of neutrophils 
was observed between aged WT and AEG-1KO mice, as evidenced by absence 
of Ly6G staining (Fig. 3.3). This data suggests that aging-associated chronic 
inflammatory responses are blunted in AEG-1KO mice. 
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Figure	  3.3.	  Ly6G	  staining	  for	  neutrophils	  in	  liver	  sections	  of	  aged	  (16	  m)	  WT	  and	  AEG-­‐
1KO	  mouse.	  Magnification:	  400X.	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B. AEG-1KO Mice are Resistant to Experimental Hepatocarcinogenesis 
 WT and AEG-1KO mice were given a single i.p. injection of DEN (30 
ug/gm) and tumorigenesis was monitored at 32 weeks. Compared to WT mice, 
AEG-1KO mice showed profound resistance to DEN-induced HCC. AEG-1KO 
mice either resisted tumorigenesis altogether or developed very small nodules 
(<2mm) (Table 3.3 and Fig. 3.4A). WT livers presented with AFP-positive HCC 
with vascular invasion (arrow in Fig. 3.4B) and high AEG-1 expression, while the 
liver architecture was preserved in AEG-1KO mice (Fig. 3.4B). Serum levels of 
aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline 
phosphatase (Alk Phos) were significantly higher in WT mice as compared to 
AEG-1KO mice indicating liver damage (Fig. 3.4C).  
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Figure	  3.4.	  AEG-­‐1KO	  mice	  are	  resistant	  to	  experimental	  hepatocarcinogenesis.	  A.	  
Representative	  photograph	  of	  the	  livers	  of	  WT	  and	  AEG-­‐1KO	  mice	  32	  weeks	  after	  DEN	  
injection.	  B,	  top	  panel,	  H	  &	  E	  staining	  of	  liver	  sections;	  middle	  panel,	  AFP	  staining	  of	  the	  
liver	  sections;	  bottom	  panel,	  AEG-­‐1	  staining	  of	  the	  liver	  sections.	  These	  samples	  were	  
collected	  at	  32	  weeks	  after	  DEN	  injection.	  C.	  Serum	  levels	  of	  the	  indicated	  liver	  enzymes	  
at	  the	  end	  of	  the	  study.	  AST:	  aspartate	  aminotransferase,	  ALT;	  alanine	  aminotransferase	  
and	  Alk	  Phos:	  alkaline	  phosphatase.	  Data	  represent	  mean	  ±	  SEM.	  n	  =	  12	  for	  WT	  and	  n	  =	  
8	  for	  AEG-­‐1KO.	  *:	  p<0.01.	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Table	  3.3.	  Number	  of	  liver	  nodules	  in	  DEN-­‐treated	  WT	  and	  AEG-­‐1KO	  mice.	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One important aspect of AEG-1 is its ability to induce metastasis. We 
therefore tested a more aggressive experimental procedure where tumorigenesis 
was induced by injection of DEN (10 ug/gm) and then it was promoted by 
providing phenobarbital (PB; 0.05%) daily in drinking water. Tumorigenesis was 
monitored at 28 weeks. WT mice exhibited an intensified hepatocarcinogenic 
response evidenced by large necrotic liver tumors with a 52% rate of lung 
metastasis (Fig. 3.5A). AEG-1KO mice remained remarkably resistant even to 
this combinatorial treatment with no distant metastasis. Histological analysis of 
liver demonstrated HCC in WT mice (Fig. 3.5B). Although some level of 
dysplasia was observed in AEG-1KO mice, frank HCC was not detected. The 
metastatic nodules in the WT lung were positive for AFP indicating that the 
nodules originated in the liver (Fig. 3.5C). 
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Figure	  3.5	  AEG-­‐1KO	  mice	  are	  resistant	  to	  experimental	  hepatocarcinogenesis	  and	  
metastasis.	  A.	  Representative	  photograph	  of	  the	  livers	  of	  WT	  and	  AEG-­‐1KO	  mice	  28	  
weeks	  after	  initial	  DEN	  injection	  receiving	  PB	  in	  drinking	  water.	  B.	  H	  &	  E	  staining	  of	  liver	  
sections	  at	  28	  weeks.	  C.	  top	  panel,	  H	  &	  E	  staining	  of	  the	  lungs	  showing	  lung	  metastasis	  
in	  WT	  mouse;	  bottom	  panel,	  AFP	  staining	  of	  a	  metastatic	  lung	  tumor	  in	  WT	  mouse.	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Staining for macrophage marker F4/80 showed significant infiltration of 
macrophages both in DEN- and DEN/PB-treated WT tumors but not in AEG-1KO 
livers (Fig. 3.6A). Quantification of macrophage infiltration is shown in (Fig. 3.6B). 
We stained DEN-treated WT and AEG-1KO liver for α-smooth muscle actin (α-
SMA) as an indicator of activation of stellate cells and fibrogenic response. A 
substantial increase in α-SMA staining was observed in the tumor in WT mice 
when compared to non-tumor region (Fig. 3.6C). α-SMA staining in AEG-1KO 
liver was similar to that in the non-tumor region of WT liver. 
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Figure	  3.6	  Macrophage	  and	  Stellate	  cell	  activity	  in	  the	  liver	  of	  AEG-­‐1	  and	  WT	  mice.	  A.	  
F4/80	  staining	  for	  macrophages	  in	  liver	  sections	  of	  WT	  and	  AEG-­‐1KO	  mice	  treated	  with	  
DEN	  alone	  (top	  panels)	  or	  DEN/PB	  (bottom	  panels).	  B.	  Graphical	  representation	  of	  
quantification	  of	  F4/80	  staining	  for	  macrophages	  in	  liver	  sections	  of	  WT	  and	  AEG-­‐1KO	  
mice	  either	  untreated	  (naïve)	  or	  treated	  with	  DEN	  or	  DEN/PB.	  N=3/group.	  At	  least	  9	  
fields	  were	  counted	  for	  each	  mouse	  section.	  Data	  represent	  mean	  ±	  SEM.	  *:	  p<0.01.	  C.	  
Stellate	  cells	  are	  activated	  in	  the	  tumor	  region	  of	  WT	  liver.	  DEN-­‐treated	  liver	  sections	  
from	  WT	  and	  AEG-­‐1KO	  mice	  were	  stained	  for	  α-­‐SMA.	  Note	  increased	  staining	  for	  α-­‐SMA	  
only	  in	  the	  tumor	  of	  WT	  mouse.	  Magnification	  200X.	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A possible cause of the pronounced resistance of AEG-1KO mice to DEN-
induced HCC might be improper metabolism of DEN in these mice so that DEN 
is not capable of adequately damaging hepatocytes. To rule out this possibility 
we injected WT and AEG-1KO 2 wks old pups with DEN and then measured 
serum liver enzymes 48 h later. Both WT and AEG-1KO mice showed significant 
induction of liver enzymes indicating that DEN could damage both WT and AEG-
1KO hepatocytes in a similar manner (Table 3.4). 
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Table	  3.4.	  Liver	  enzyme	  levels	  in	  mouse	  sera	  48	  h	  after	  injection	  of	  DEN.	  Three	  WT	  and	  
three	   AEG-­‐1KO	  mice	   were	   used,	   10	   μg/gm	   of	   DEN	   was	   delivered	   by	   intra	   peritoneal	  
injection.	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C. Growth Factor Signaling is not Altered in AEG-1KO Mice 
 Activation of pro-survival signaling pathways, such as PI3K/AKT, 
MEK/ERK and β-catenin, have been shown to play a role in mediating oncogenic 
effects of overexpressed AEG-1 in human HCC cells as well as in Alb/AEG-1 
mice. We treated naïve primary WT and AEG-1KO hepatocytes with epidermal 
growth factor (EGF) (50 ng/mL) and analyzed temporal activation of EGFR, AKT 
and ERK1/2. Both WT and AEG-1KO hepatocytes showed similar kinetics and 
magnitude of activation suggesting that AEG-1 does not modulate growth factor 
signaling under physiological conditions (Fig. 3.7). Similarly no difference was 
observed in the activated (phosphorylated) forms of AKT, ERK1/2 and β-catenin 
in adult WT and AEG-1KO liver samples under normal basal conditions (Fig. 
3.8A). These results indicate that AEG-1 is not required for physiological 
regulation of Akt, ERK1/2 and β-catenin. We next evaluated the activation of 
these signaling pathways in DEN-treated WT and AEG-1KO liver samples (Fig. 
3.8B). No significant difference was observed in the activation of AKT, ERK1/2 
and β-catenin in the two groups. In naïve mice, inhibition in activated STAT3 and 
p65 NF-κB, known regulators of HCC, was observed in AEG-1KO livers versus 
WT (Fig. 3.9A). DEN-treatment induced a robust activation of both p-p65 (NF-κB) 
and p-STAT3 in WT mice but not in AEG-1KO mice (Fig. 3.9A). These findings 
were confirmed by immunohistochemistry (IHC) in DEN-treated liver samples 
(Fig. 3.9B). In addition, DEN-treatment induced a significant increase in IL-6 
protein level in liver homogenates of WT but not in AEG-1KO mice (Fig. 3.10). 
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Figure	  3.7	  Knockout	  of	  AEG-­‐1	  does	  not	  affect	  hepatocyte	  response	  to	  growth	  factors	  
WT	  and	  AEG-­‐1KO	  hepatocytes	  were	  treated	  with	  EGF	  (50	  ng/mL)	  for	  the	  indicated	  time	  
points	  and	  Western	  blotting	  was	  performed	  for	  the	  indicated	  proteins	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Figure	  3.8	  Pathway	  activation	  in	  naïve	  and	  DEN	  treated	  livers.	   A.	  Western	  blot	  was	  
performed	  for	  the	  indicated	  proteins	  using	  liver	  lysates	  from	  adult	  WT	  and	  AEG-­‐1KO	  
mice.	  B.	  Western	  blotting	  was	  performed	  for	  the	  indicated	  proteins	  using	  liver	  lysates	  
from	  DEN-­‐treated	  WT	  and	  AEG-­‐1KO	  mice	  at	  the	  end	  of	  the	  study.	  Each	  lane	  represents	  
one	  independent	  mouse.	  
A. 
B. 
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Figure	  3.9	  NF-­‐κB	  and	  STAT3	  activation	  is	  inhibited	  in	  AEG-­‐1KO	  mice.	  A.	  Western	  
blotting	  was	  performed	  for	  the	  indicated	  proteins	  using	  liver	  lysates	  from	  naïve	  and	  
DEN-­‐treated	  WT	  and	  AEG-­‐1KO	  mice	  at	  the	  end	  of	  the	  study.	  Each	  lane	  represents	  one	  
independent	  mouse.	  B.	  DEN-­‐treated	  liver	  sections	  were	  stained	  for	  p-­‐STAT3	  and	  p-­‐p65	  
NF-­‐κB	  at	  the	  end	  of	  the	  study.	  
A. 
B. 
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Figure	  3.10	  IL-­‐6	  protein	  level	  was	  measured	  in	  DEN-­‐treated	  liver	  homogenates	  by	  
ELISA.	  Data	  represent	  mean	  ±	  SEM.	  n	  =	  5.	  *:	  p<0.01.	  
 
	  
	  	   127	  
D. NF-κB Activation is Abrogated in AEG-1KO Mice 
 We measured NF-κB luciferase reporter activity in primary hepatocytes 
isolated from WT and AEG-1KO mice. Both basal and LPS-induced luciferase 
activity was significantly blunted in AEG-1KO hepatocytes when compared to WT 
hepatocytes (Fig. 3.11A). As a corollary LPS-induced phosphorylation (Fig. 
3.11B) and nuclear translocation (Fig. 3.12) of the p65 subunit of NF-κB and 
induction of NF-κB-target genes IL-1β and IL-6 (Fig. 3.11C) were significantly 
abrogated in AEG-1KO hepatocytes versus WT hepatocytes. Since NF-κB 
activation in macrophages is crucial for HCC, we next analyzed peritoneal 
macrophages isolated from WT and AEG-1KO mice. 
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Figure	  3.11	  NF-­‐κB	  activation	  is	  inhibited	  in	  AEG-­‐1KO	  hepatocytes.	  A.	  NF-­‐κB	  luciferase	  
reporter	  activity	  was	  measured	  in	  WT	  and	  AEG-­‐1KO	  hepatocytes.	  Firefly	  luciferase	  
activity	  was	  normalized	  by	  Renilla	  luciferase	  activity.	  The	  activity	  of	  empty	  pGL3-­‐basic	  
vector	  was	  considered	  as	  1.	  R.L.U.:	  Relative	  luciferase	  units.	  Data	  represent	  mean	  ±	  SEM	  
of	  three	  independent	  experiments.	  *:	  p<0.01.	  B.	  WT	  and	  AEG-­‐1KO	  hepatocytes	  were	  
treated	  with	  LPS	  for	  the	  indicated	  time	  points	  and	  Western	  blotting	  was	  performed	  for	  
the	  indicated	  proteins.	  C.	  WT	  and	  AEG-­‐1KO	  hepatocytes	  were	  treated	  with	  LPS	  for	  4	  h	  
and	  the	  mRNA	  level	  of	  Il1b	  and	  Il6	  was	  measured	  by	  Taqman	  Q-­‐RT-­‐PCR.	  Data	  represent	  
mean	  ±	  SEM	  of	  three	  independent	  experiments.	  *:	  p<0.01.	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Figure	  3.12	  NF-­‐κB	  localization	  is	  inhibited	  in	  AEG-­‐1KO	  hepatocytes.	  
Immunofluorescence	  followed	  by	  confocal	  microscopy	  of	  WT	  and	  AEG-­‐1KO	  hepatocytes	  
after	  LPS	  treatment	  for	  30	  min	  showing	  p65	  nuclear	  translocation.	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 AEG-1 mRNA expression in macrophages was significantly higher 
compared to that in hepatocytes (Fig. 3.12). In primary hepatocytes AEG-1 is 
localized predominantly in the nucleus while in macrophages it is located both in 
the nucleus and in the cytoplasm (Fig. 3.13A). Upon LPS treatment nuclear 
translocation of p65 NF-κB was substantially abrogated in AEG-1KO 
macrophages compared to WT macrophages (Fig. 3.13B). LPS-mediated 
induction of IL-6 and IL-1β was also markedly blunted in AEG-1KO peritoneal 
macrophages versus WT (Fig. 3.14A-B). We collected conditioned media (CM) 
from LPS-treated WT and AEG-1KO hepatocytes and treated WT and AEG-1KO 
macrophages with the CM. CM from WT hepatocytes induced IL-6 mRNA 
expression only in WT macrophages but not in AEG-1KO macrophages (Fig. 
3.14C). Additionally CM from AEG-1KO hepatocytes failed to induce IL-6 mRNA 
in either WT or AEG-1KO macrophages.  
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Figure	  3.13	  AEG-­‐1	  Expression	  in	  primary	  mouse	  hepatocytes	  and	  macrophages.	  	  mRNA	  
level	  in	  hepatocytes	  and	  macrophages	  of	  WT	  mice	  measured	  by	  Taqman	  Q-­‐RT-­‐PCR.	  
A.U.:	  arbitrary	  unit.	  Data	  represent	  mean	  ±	  SEM	  of	  three	  independent	  experiments.	  *:	  
p<0.01.	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Figure	  3.14	  Subcellular	  localization	  of	  AEG-­‐1	  in	  WT	  hepatocytes	  and	  macrophages.	  
Immunofluorescence	  staining	  showing	  subcellular	  localization	  of	  AEG-­‐1	  in	  WT	  
hepatocytes	  and	  macrophages.	  F4/80	  staining	  was	  performed	  in	  macrophages	  to	  
demonstrate	  authenticity	  of	  purification. 
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Figure	  3.15	  NF-­‐κB	  translocation	  is	  abrogated	  in	  AEG-­‐1KO	  macrophages.	  
Immunofluorescence	  followed	  by	  confocal	  microscopy	  of	  WT	  and	  AEG-­‐1KO	  
macrophages	  after	  LPS	  treatment	  for	  30	  min	  showing	  p65	  nuclear	  translocation.	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Figure	  3.16	  NF-­‐κB	  signaling	  is	  inhibited	  between	  AEG-­‐1KO	  hepatocytes	  and	  
macrophages.	  WT	  and	  AEG-­‐1KO	  macrophages	  were	  treated	  with	  LPS	  for	  12	  h	  and	  the	  
mRNA	  levels	  of	  Il1b	  (A)	  and	  Il6	  (B)	  were	  measured	  by	  Taqman	  Q-­‐RT-­‐PCR.	  C.	  WT	  and	  AEG-­‐
1KO	  macrophages	  were	  treated	  with	  conditioned	  media	  (CM)	  from	  LPS-­‐treated	  WT	  and	  
AEG-­‐1KO	  hepatocytes	  and	  Il6	  mRNA	  expression	  was	  measured	  by	  Taqman	  Q-­‐RT-­‐PCR	  4	  h	  
later.	  For	  D-­‐F,	  data	  represent	  mean	  ±	  SEM	  of	  three	  independent	  experiments.	  *:	  p<0.01.	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 To extend these observations further we performed RNA-sequencing 
analysis using liver samples from WT and AEG-1KO mice. Using cut-off of Log2 
fold-change of 1.5 or -1.5, 597 genes showed differential change, out of which 
247 genes were upregulated and 350 genes were downregulated in AEG-1KO 
liver versus WT liver. These differentially expressed genes were analyzed using 
Ingenuity pathway analysis software. The data were analyzed to identify the 
upstream regulators the activation or inhibition of which might lead to alterations 
in downstream genes. An activation z-score >2 indicates activation and a score 
of <-2 indicates inhibition. The most significant inhibition (p<0.02) was observed 
for genes downstream of IL-6, IL-1B, TNF family, IL17RA and NF-κB complex. 
These upstream regulators were analyzed for regulator effects to predict 
functional endpoints. It was observed that collective inhibition of these genes 
leads to suppression of movement of myeloid cells and decreased activation of 
granulocytes (Fig. 3.17). These analyses further support our hypothesis that 
inhibition of activation of myeloid cells is the major mechanism for resistance of 
AEG-1KO mice for developing HCC.  
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Figure	  3.17	  Molecular	  mechanisms	  rendering	  AEG-­‐1KO	  mice	  resistant	  to	  HCC.	  
Functional	  end-­‐points,	  analyzed	  by	  Ingenuity	  pathway	  analysis,	  that	  are	  inhibited	  in	  
AEG-­‐1KO	  mice.	  Blue	  line:	  inhibition;	  red	  line:	  activation;	  yellow	  line:	  finding	  inconsistent	  
with	  state	  of	  downstream	  molecules;	  gray	  line:	  effect	  not	  predicted.	  Green	  color:	  
downregulation	  of	  expression;	  red	  color:	  upregulation	  of	  expression.	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Figure	  3.18	  Schematic	  representation	  of	  the	  molecular	  mechanism	  of	  resistance	  of	  
AEG-­‐1KO	  mice	  to	  HCC.	  	  In	  WT	  mice	  DEN-­‐induced	  hepatocyte	  injury	  leads	  to	  IL-­‐1α	  
production	  that	  activates	  NF-­‐κB	  in	  the	  macrophages	  leading	  to	  production	  of	  IL-­‐6.	  IL-­‐6	  
activates	  STAT3	  in	  hepatocytes	  facilitating	  proliferation	  of	  the	  mutated	  cells	  leading	  to	  
HCC.	  In	  AEG-­‐1KO	  mice	  NF-­‐κB	  activation	  is	  inhibited	  in	  hepatocytes	  and	  macrophages	  
thereby	  inhibiting	  IL-­‐6	  production	  and	  STAT3	  activation.	  As	  a	  consequence,	  HCC	  
development	  is	  significantly	  abrogated.	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V. Discussion 
 The observation that Alb/AEG-1 mice do not develop spontaneous HCC 
[54] prompted us to hypothesize that AEG-1 is not able to transform hepatocytes, 
hence it is not required for initial development of HCC. In human HCC cells, 
overexpression of AEG-1 or knockdown of AEG-1 markedly affects invasion, 
angiogenesis and metastasis, and in comparison the effects on cell proliferation 
is significant but small [51]. In breast cancer cells modulation of AEG-1 does not 
affect proliferation at all, rather all phenotypes are reflected in more aggressive 
behavior, such as invasion and metastasis [2, 9]. These findings lead to the 
conclusion that the primary role of AEG-1 is to promote aggressive behavior and 
owing to its profound effect on metastasis, it was named Metadherin [2]. Our 
studies using AEG-1KO mice demonstrate for the first time that even after a 
mutagenic effect, such as by DEN, AEG-1 is required for initial development of 
the tumor, at least in the context of HCC. We document that abrogation of NF-κB 
signaling in hepatocytes and the tumor microenvironment cells, such as 
macrophages, might be the underlying mechanism that prevents paracrine 
signaling from macrophages to stimulate mutated hepatocytes to proliferate. 
Upon DEN treatment a significant decrease in activated NF-κB and STAT3 and 
IL-6 levels was observed in AEG-1KO livers versus WT providing supporting 
evidence for our hypothesis. In the short-term experiment DEN was able to 
cause liver damage to both WT and AEG-1KO mice indicating that the tumor-
inhibitory effect observed in AEG-1KO mice is not because of ablation of DEN 
effect. Damaged hepatocytes release factors, such as IL-1β, that activate NF-κB 
in macrophages leading to secretion of IL-6 that stimulates STAT3 activation in 
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hepatocytes promoting their proliferation [107]. In AEG-1KO mice, inhibition of 
NF-κB activation in macrophages stalls the subsequent processes, therefore, 
profoundly abrogating initial development of the tumor (Fig. 3.18). This scenario 
might be applicable to other cancers as well since chronic inflammation is a core 
component of almost all cancers. Indeed, AEG-1KO mice show low basal level of 
inflammation, which might protect them from spontaneous tumorigenesis as 
observed in aged WT mice.  
 Multiple studies have documented the important roles of PI3K/AKT, MAPK 
and Wnt/β-catenin signaling pathways in mediating oncogenic functions of 
overexpressed AEG-1 [51, 52, 57]. However, AEG-1KO hepatocytes do not show 
abrogated response upon EGF stimulation when compared to WT, and no 
difference was observed in the activated status of AKT, ERK1/2 and β-catenin in 
the livers of WT and AEG-1KO mice under basal condition or upon DEN 
treatment. These observations might be explained by the localization of AEG-1 in 
normal hepatocytes versus HCC cells. In normal hepatocytes AEG-1 is almost 
exclusively located in the nucleus [54]. In cancer cells overexpressed AEG-1 is 
monoubiquitinated, which facilitates its cytoplasmic accumulation [13, 54]e. In the 
cytoplasm overexpressed AEG-1 might exert promiscuous interaction with other 
signaling molecules leading to their activation, a function that is attributed to 
oncogenic AEG-1 but not under physiological condition.  
 The observation that AEG-1 is required for NF-κB activation in 
macrophages has profound implications in diverse physiological and pathological 
states. Activation of NF-κB pathways in dendritic cells is essential for their 
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optimal functioning, including antigen processing and presentation [117]. Using 
the human promonocytic cell line U937, it was documented that LPS induces 
AEG-1 and this induction is required for subsequent NF-κB activation [16]. 
Additionally, NF-κB activation is required for LPS-induced AEG-1 induction thus 
establishing a positive feedback loop between AEG-1 and NF-κB. NF-κB 
activation is a key requirement for generating interferon-induced anti-viral 
immunity. Thus AEG-1 might be a key component regulating immune function. 
Additionally AEG-1 might be a key regulator of chronic inflammatory diseases. 
In summary, our studies unravel a novel and important role of AEG-1 in 
regulating inflammation and activation of cells in the tumor microenvironment. 
AEG-1KO mice will be a valuable tool to interrogate in detail the role of AEG-1 in 
physiological regulation of immunity and inflammation and diseases generated 
from deregulation of these systems. 
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 Chapter Four- Summary, Future Directions and Perspectives 
 
 Since the initial cloning of AEG-1, numerous research groups have 
focused on outlining the effects of AEG-1overexpression in cancer. The resultant 
body of work has soundly established the role of AEG-1 as a bona fide oncogene 
overexpressed in all cancers studied to date [54]. Similarly the pathway 
dysregulation, which characterizes AEG-1 overexpession, has been well 
described. However up until now, very few studies directly addressed the role of 
AEG-1 in normal physiology making it difficult to truly understand of broader 
implications of its dysregulation in the context of cancer. To address this gap in 
the literature we developed a germline AEG-1KO mouse. The insights gained 
from characterization of this novel mouse model have been presented here. In 
chapter two a novel function of AEG-1 as a modulator of lipid metabolism is 
described. Compared to WT, AEG-1KO mice were significantly leaner with 
markedly less body fat which. Our studies show that this was a result of 
decreased fat absorption from the intestines. AEG-1 interacts with RXR and 
inhibits RXR function. In enterocytes of AEG-1KO mice we observed increased 
activity of specific RXR heterodimer partners, LXR and PPAR-α, key inhibitors of 
intestinal fat absorption. Inhibition of fat absorption in AEG-1KO mice was further 
augmented when fed high fat diet (HFD) providing ligands to LXR and PPARα. 
Evidence of the mechanism conferring this phenotype was provided by functional 
assays. ChIP analysis and β-oxidation assays revealed increased activation of 
LXR target genes and FA oxidation respectively in AEG-1KO mice.  These 
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studies reveal a novel role of AEG-1 in regulating nuclear receptors controlling 
lipid metabolism. AEG-1 might significantly modulate the effects of HFD, and 
thereby function as a unique determinant of obesity. Specific targeting of AEG-1 
may be a viable therapeutic approach for the treatment of obesity. 
 Numerous epidemiological studies have correlated overweight and obesity 
to a substantial increase in cancer risk [118] [119] [120]. Obesity has also been 
consistently shown to increase rates of breast cancer in postmenopausal women 
by 30–50% [121] [122] [123]. Women with a BMI ≥ 40.0 have breast cancer 
death rates that are three times higher than very lean women (BMI < 20.5), this 
combined with mortality and survival studies demonstrate that excess body fat 
associates strongly with 1) reduced likelihood of survival and 2) increased 
likelihood of relapse regardless of menopausal status [124] [125]. Increased 
incidence of endometrial cancer in obese women has also been reported [126].  
Studies show that even a modest elevation in BMI to the 25–30 range has been 
shown to significantly increase the risk of death due to pancreatic cancer, 
cancers of the gastrointestinal (GI) tract, kidney as well as HCC. Even more 
strikingly a recent study documented that a BMI of 35–40 is correlated to an 
astounding 4.5-fold increase in relative HCC risk in men [120]. HCC represents 
approximately 90% of primary liver cancers and is also marked by significant 
AEG-1 overexpression when compared to the normal liver [51]. Liver-specific 
AEG-1 transgenic mice also exhibit have an overweight phenotype with an 
increased propensity towards liver steatosis [54] . Taken together this data 
strongly suggests a link between dysregulation of AEG-1 and the increased risk 
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cancer associated with obesity, thus therapeutic targeting of AEG-1 in this 
context may be beneficial to both pathologies. 
 The implication of this research stretches beyond cancer. Nuclear 
receptors maintain cellular and organismal homeostasis by serving as ligand-
activated transcription factors function. AEG-1 modulation of nuclear receptor 
function may also be important in maintaining homeostasis of hormone, vitamin 
and lipid signaling, inflammation, and myriad other biological and physiological 
processes. The highly conserved signature LXXLL sequence identified with in the 
AEG-1 protein has been demonstrated to a large number of mediate coactivator–
nuclear receptor interactions including retinoic acid receptor (RAR), thyroid 
hormone receptor (TR) and vitamin D receptor (VDR). Additional studies are 
needed to analyze the specific impact of AEG-1 expression on the activation 
status of these and other nuclear receptors.  
The link between inflammation and cancer has also been well described 
[127] [128, 129]. An estimated 15% of human cancers are associated with 
chronic infections and inflammation [130].	  Among the infectious agents related to 
the pathogenesis of cancer we find bacteria such as Helicobacter pylori in gastric 
cancer and gastric mucosal lymphoma [134]. Proinflammatory conditions not 
related to microbial infections have also been linked to the increased cancer risk. 
Such are the cases of autoimmune diseases like inflammatory bowel disease, in 
which the severity of inflammation correlates with the risk of colorectal cancer, 
[135] chronic airway irritation and inflammation by tobacco smoke or airborne 
particles in lung carcinoma [136], or chronic inflammation of unknown origin in 
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the development of prostate cancer [137]. Indeed the majority of cases of HCC 
also arise in a setting of chronic inflammation, such as infection with HBV or 
HCV, alcoholism and non-alcoholic fatty liver disease (NAFLD) [131, 132]. In 
chapter three we provide evidence that AEG-1 is required for the onset and 
progression of DEN induced HCC. We also show that NF-κB and STAT3 
signaling is abrogated in AEG-1KO hepatocytes and macrophages supporting 
previous reports of an interaction between the two proteins [11, 12]. Previous 
studies show that NF-κB activation in hepatocytes is necessary in inflammation-
induced HCC [102]. NF-κB-regulated expression of the STAT3-activating 
cytokine IL-6 has recently been identified in viral hepatitis and in hepatosteatosis 
[133]. Additionally, inhibition or genetic deletion of IL-6 has been shown to 
provide a significant reduction in tumor load [106]. Injury to hepatocytes, such as 
those caused by DEN, leads to release of IL-1α that activates NF-κB in liver 
macrophages (Kupffer cells) with subsequent release of cytokines, such as IL-6 
[106-108]. IL-6 promotes proliferation and survival of hepatocytes by activating 
Stat3 signaling [106]. While the AEG-1KO mouse provided valuable insights 
about the role of AEG-1 in these signaling cascades there were limitations to 
studying this genome wide knockout. For instance, it was difficult to identify the 
specific role of AEG-1 expression in each cell type of the tumor 
microenvironment. To better understand where AEG-1 fits into this cascade we 
have also generated liver-specific and macrophage-specific AEG-1KO mice. 
These mice, particularly the macrophage-specific KOs will be useful not only to 
the investigation of HCC but also to other inflammation-associated cancers. More 
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broadly, analysis of the macrophage-specific AEG-1KO mouse will be a useful 
tool to interrogate the role of AEG-1 in the immune response. We see that AEG-
1KO mice have an impaired response to the inflammation-linked DEN 
carcinogenesis model leading us to question the integrity of their overall immune 
response. These and other questions will be addressed in forthcoming 
experiments.  
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